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Abstract 
In the coming years, genetic test results will be increasingly used as indicators that 
influence medical decision-making. With chronic disease on the rise and the 
continuing global spread of infectious disease, novel instruments able to detect 
relevant mutations in a point-of-care setting are being developed to facilitate this 
increased demand in personalized health care. However, diagnosis for such demand 
often requires laboratory facilities and skilled personnel, meaning that diagnostic tests 
are restricted by time and access. This thesis presents a novel configuration for Ion 
sensitive Field Effect Transistors (ISFETs) to be used as a threshold detector during 
nucleic acid base pairs match. ISFET-based inverters are used as reaction threshold 
detectors to convey the chemical reaction level to a logic output once a threshold has 
been reached. Using this method, novel DNA logic functions are derived for 
nucleotides allowing local digital computations. 
The thesis also presents business models that enable such technology to be utilised in 
point of care applications, and experiment as results and business models given for an 
HIV point of care example are proposed.  
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CHAPTER 1  – INTRODUCTION 
As we enter a new wave of technology inspired by lifestyle and healthcare, precise 
and efficient point of care testing is becoming increasingly important. The technology 
to accurately detect a gene sequence in real-time would provide end-users with 
personal medical care yet is unavailable outside a laboratory. This presents 
opportunities in areas where a real-time result can save time, money and lives [1].  
Contemporary sequencing and genotyping technologies are expensive, time 
consuming and laboratory based. However, rapid progress in genome science puts on 
a new horizon for low-density genotyping in POC settings. A robust, low cost, and 
laboratory free genotyping platforms are essential features in POC settings, which 
allow low-density genotyping to be extremely cost efficient without using heavy 
laboratory equipment and skilled personal.  
1.1 DNA LOGIC 
For year scientists have been trying to implement digital computations in cells by 
creating in-vivo digital logic circuits using DNA binding Proteins, and gene 
expression. Now, using the ISFET method for detection of nucleic acid, we are able to 
achieve digital computation out of biological cells and their genetics. It is the 
intention of this research to propose a novel method of DNA Logic using silicon 
based transistors with chemical interactions to create so called DNA switches that 
may perform in-vitro computation. This particular work will be confined to switching 
based upon the marker for nucleotide insertions (SNPs) with the application being 
diagnostics. It is not the intention of this research to develop a point-of-care genetic 
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testing device but rather to add some intelligence to the sensors so that local 
processing and computation of SNPs can be realized in real-time. 
1.2 CHEMICAL SENSOR 
A chemical sensor is generally comprised of sensing element, transducer, and the 
readout circuit. The sensing element is the sensing membrane in the case of ISFET, 
which can be silicon nitride or other oxides. The evaluation of sensor performance is 
generally done by a table of sensor characters. Specificity and sensitivity are the two 
basic characters that chemical sensors are evaluated by the users and regulated by the 
authorities [2, 3]. Common complications of chemical sensors includes hysteresis, 
baseline drift, fineness and cross reactivity [4]. Scientists have been working to 
optimise these issues in which sensors deviate from the ideal. By merging and 
integrating chemical sensing with electronic signal processing circuitry, many 
undesirable characteristics of chemical sensing can be mitigated through drift 
compensation or intelligent processing on heterogeneous sensors to improve 
selectivity [5]. 
1.3 BIO SENSING 
A biosensor is a chemical sensor that integrates a bio-component with a 
physicochemical component for the purpose of detecting an analyte [6]. The sensor 
uses a biological recognition layer to bind with the concentration of the target species 
to a transducer, as we can see in  [7]. Various applications have been employed using 
biosensors in past twenty years, including environmental analysis, medical treatments, 
toxicology studies and military defences [8-11]. The two major challenges in 
developing a biosensor are stability and reproducibility. The sensor often lacks the 
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capacity for continuous monitoring, rapid response times, intelligence and portability. 
[11]  
We can categorize biosensors into two groups by the nature of the biological 
recognition process. [12] The first group, biocatalytic sensors, uses enzymes, cells or 
tissues as immobilized components. The second group, affinity sensors, are based on 
the recognition process of antibodies, membrane receptors or nucleic acids. In certain 
transduction mode, biosensors can be made in the solid-state to provide chip-based 
sensing of biomolecules, cells, neurons and nucleic acids. [13]  
 
Figure 1-1 Biosensor architecture  
1.4 ISFET PLATFORM HIV NUCLEIC ACID TEST 
The key objectives are to implement HIV detection in a point of care setting and bring 
personalized medicine to the bedside in the management of infected patients with 
HIV. In addition to its timeliness in developing Point of Care (POC) testing which 
will be of immediate benefit to patients, the section will serve as a proof of principle 
for POC detection of other host genetic polymorphisms and the detection and 
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quantification of infectious organisms. The work will also be important in the 
development of lab-free diagnostics needed in the developing world and for other 
diseases.  
1.5 RAPID HIV TESTING KIT: BUSINESS MODEL OVERVIEW 
With healthcare budgets already overstretched and fewer careers – professional and 
non-professional – available to meet these increased needs, the forecasted additional 
demands are simply unsustainable using current practice. Factoring in the growing 
patient demands for personalized treatment, medicine and services, it results in huge 
cost pressures on healthcare. A new paradigm is required. Using the ISFET 
technology, we propose a novel business model where selling nucleic acid testing 
machines to point of care facilities and institutions is realised.  
In summary the thesis will discuss the novel application of nucleic acid detection 
based upon a semiconductor approach using ISFETs. The concept of DNA logic is 
then invented as a means of implementing logical functions of genetic information. 
The application to the SNP detection as a point of care means for any application is 
then experimentally confirmed.  In the final chapter, the application of the DNA 
Logic technique is applied to a novel HIV point of care detection system and 
experimental results are presented. The final chapter discusses the market potential of 
the technology and the business model followed by concluding remarks and future 
applications.  
 
 
26 | P a g e  
 
1.6 SOLID-STATE ELECTROCHEMICAL SENSING 
Electrochemical sensing is a practice of detecting targeted species through electrons 
or by ion transfer across an electrolyte/electrode interface. Since the 1930s, 
electrochemical sensing has been widely used in practice. It is a very matured and 
well-characterized transduction method. [7] 
Driven by commercial success in various applications, researches for more advance 
solid-state physical sensors have begun looking towards developments in fabricating 
chemical sensors on a semiconductor substrate. This will benefit the sensors by 
lowering manufacturing costs, standardizing wafer fabrication processes and 
integrating sensors with electronic circuitry. [14, 15] 
There are clear advantages of utilising solid-state technologies in chemical sensing 
application. The approach leverages the great investment of solid-state sensor industry 
to meet the demand of better chemical sensors. The biological research works have 
consistently making new discoveries about the analytes and the corresponding ligands. 
The integration of the new ligands on solid-state sensors is possible due to the 
transduction nature of the ion or electron transfer of the targeted species and the solid-
state substrate binding at the sensor surface. In addition, electrochemical detection is 
relatively more cost effective over other alternative solid-state transduction modes, 
which require lenses and fluorescent labels for detection. [4, 16] 
In spite of many advantages with using electrochemical sensors, many of the 
undesirable characteristics mentioned in  have not yet been overcome. Thus, till 
present day, researches to improve sensors performance has been an on-going 
assignment for many physicians and engineers. 
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1.7 SOLID-STATE ELECTROCHEMICAL MICROSENSOR 
TECHNOLOGIES 
A solid-state micro-sensor is defined as a solid-state sensor embedded with sensing 
elements such that the physical dimensions are on the sub-millimetre scale and often 
as planar devices, fabricated using procedures from the microelectronics industry. 
Low cost, small dimensions, high reproducibility and integratability to electronic 
circuitry are several key advantages of solid-state electrochemical micro-sensors. [17] 
This section reviews various solid-state electrochemical micro-sensor technologies 
and their compatibility with the complementary metal oxide semiconductor (CMOS) 
fabrication process.  
1.7.1 SENSOR MICROFABRICATION AND CMOS COMPATIBILITY 
Sensor micro-fabrication is similar to semiconductor device fabrication. The main 
difference between them is the planar electrodes formed on the solid-state 
electrochemical sensors substrates. The substrates can be made of ceramic, glass, 
plastic and silicon to endure insertion into acids and bases, and to be resistive to 
various environmental conditions and physical deformation. By implementing thick-
film lithography of conducting pastes, or by thin-film metal deposition processes, 
electrodes can be patterned onto substrates [16]. 
Using batch fabrication techniques and lithographic processing, sensor micro-
fabrication is very low cost per sensor with high reproducibility. CMOS is the current 
industry standard in terms of the production technology for high performance digital 
and analogue integrated circuits. Its fabrication process is highly standardized and 
well characterized. CMOS-fabricated systems are currently the best method for the 
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realization of a minimum cost per sensor, minimum feature size and minimum 
process variation [18]. However, only a fraction of solid-state electrochemical sensors 
can be produced using generic CMOS process. The major limitations are due to 
restrictions on the process flexibility in commercial foundries.  
1.7.2 CONDUCTIMETRIC MICROSENSORS 
The conductimetric microsensor is based on the measurement of the conductivity of a 
sample to find out the concentration of charges in a solution. Therefore any particular 
species in the solution will affect the measurement. Thus this is a technique which 
exhibits low selectivity as we have mentioned in . With such a property, this sensor is 
often used as an online detector after separation of a mixture of ions by ion 
chromatography [19].  
Chemiresistors and chemicapacitors are examples of conductimetric devices that 
serve as sensors for “electronic noses” and “electronic tongues”, where pattern 
recognition is more important than selectivity [20, 21].  
1.7.3 AMPEROMETRIC AND VOLTAMMETRIC MICROSENSORS 
A fixed potential is applied to a reference electrode, causing a redox reaction in the 
analyte, when implementing detection in amperometry. The reaction will trigger the 
current to flow between the electrode and a working electrode. Due to the possibility 
of causing the fixed potential to alter when current passes through the reference 
electrode, the three-electrode system is often used in practice to avoid such problems 
by adding a third electrode, known as a counter electrode.  
Voltammetric is a technique using time-varying potential where current-voltage 
profiles are recorded and thus several species reacting at different applied potentials 
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can be determined simultaneously in a single experiment. As a result, voltammetric 
provides more information than amperometry and has less limitation [22]. 
1.7.4 POTENTIOMETRIC MICROSENSORS 
Potentiometry is an electroanalytical method which is based on measurement of 
potential between two electrodes. Between the two electrodes there is only negligible 
current. The voltage is generated between an ion-selective electrode (ISE) and a 
reference electrode caused by a difference of concentration between the analyte 
solution and a reference solution. Potentiometric measurements enable selective 
detection of ions in the presence of a multitude of other substances. The reference 
electrode is normally a silver/silver chloride (Ag/AgCl) electrode used as reference.  
[23] 
 
Figure 1-2 Electrochemical cell for potentiometric measurements with an ISE 
At equilibrium, this potential is related to the ion activity 	 	on either side of the 
membrane as defined by the Nernst equation: 
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Equation 1-1 Nernst equation of potentiometric measurement of an ion-selective 
electrode [24] 

 =  
,
,  
for the ion i of charge z	, where R is the gas constant, T is absolute temperature and F 
is the Faraday constant. 
Since the activity of the ion i in the internal solution is known, then 
Equation 1-2 Ionic concentration dependence electrode potential 
E = constant + 2.303 *+,	- log	,0123  
thus giving a variation of  45.67
89
 mV in <  per decade variation in ion activity at a 
temperature of 298°>. 
FET-based chemical sensors such as the ISFET, CHEMFET, and the Work function 
FET all fall into this class whereby the charge in solution, exposed to a floating gate, 
may be sensed via a stable reference electrode.  
In this section, we have discussed various biosensors and with any chemical sensor 
priory mentioned, it is desirable to keep to minimum non-standard process steps. This 
is because such steps will increase in manufacturing complexity and thus will the cost 
per sensor. 
Sensors we have discussed prior to this section are either not CMOS-process 
compatible or post-processing is needed either to deposit electrodes on the die or 
attach membranes to make the sensors selective to specific analytes. 
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Fabrication of ISFETs can be achieved using standard MOSFETs with the native 
passivation of the CMOS process. [25] This is even so when using ISFETs as a 
proton sensor that no extra processing steps are required to deposit the 
membrane and with an external reference electrode, making the devices 
selective to other ions requires deposition of other membranes. ISFETs are an 
attractive option for proton sensing because they can take full advantage of the merits 
which come with implementation in a standard CMOS process which include 
miniaturization, repeatability, minimal process variation, high yield and low cost of 
large volumes. 
1.7.5 BENEFITS OF CHEMICAL SENSING WITH UNMODIFIED CMOS 
ISFETS 
The ISFET has great potential to be commercialized due to its unique features in 
detecting genes through chemical reaction. Potential benefits of using ISFETs to build 
such systems include: 
• Minimal or no post processing - CMOS ISFETs are inherently sensitive to 
hydrogen using the native passivation of the die [25] 
• Low power processing - Can be operated in weak inversion in which current is 
governed by diffusion to give low power operation [26] 
• Boltzmann relation to ionic current - Obeys a Boltzmann distribution in weak 
inversion which can be used to implement chemically-gated ion channels [18] 
• Monolithic integration - Can be integrated with its MOSFET counterpart to 
make differential readouts as well as to apply well-known circuit techniques 
which are used in solid-state integrated circuits. 
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• Array processing - Can be grouped into arrays to provide redundancy and 
spatiotemporal mapping 
With these in mind we proceed by describing the background of the applications of 
ISFET-based chemical sensor and operation of the ISFET. 
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CHAPTER 2 SEQUENCING AND GENOTYPING 
Molecular diagnostics is becoming a necessary tool in modern clinic practice. The 
eruption of the knowledge comes not only from the gene sequences but also mutation-
phenotype association and biomarker discoveries. Critical information such as drug 
adverse selection, viral load monitoring, and pathogen identification can be provided 
through diagnostic technologies in the molecular level for clinicians when treating 
patents. In more and more fields, molecular diagnostics are essential and the only tool 
to decide the treatment or prescription. These fields include infectious disease 
detection as well as individual variations. Examples are human leukocyte antigen 
typing (HLA) for transplant matching, mutation tests in oncology, and 
pharmacogenetic tests. These methods generally adapt the technologies that were 
originally developed in research laboratories. Generally, the clinicians in the first line 
facing patients are not trained for the skills of molecular diagnosis.  
Demand for a rapid and simple nucleic acid test has been rising rapidly and the 
market in the United States has approximately a double digit growth from 2009 to 
2010 [27]. The growth is partly due to the advance of molecular diagnostic 
technology as well as the availability of markers. Because of the short windows for 
effective action, in an area such as infectious disease control and management, rapid 
testing for nucleic acid has been needed in diagnosis as well as prognosis. 
A classic example is the management of Human immunodeficiency virus (HIV) 
infection, where the traditional detection based on immunoassay requires long turn-
around time  and lacks critical information, such as virus strain. Nucleic acid tests 
have filled the gap and provided early detection and helps with therapeutic important 
decisions. 
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The field of nucleic acid test technology has been largely dominated with real-time 
Polymerase Chain Reaction (PCR) technologies which require a molecular laboratory 
setup in clinical setting or primary care environment. These methods are established 
in commercial molecular diagnosis kits, reagents, and instruments. The majority of 
the tests employ fluorescent signal and nucleic acid amplification methods. 
A rising new era of personalized health care is demanding for rapid low-density 
genotyping in applications for quick diagnostics, drug efficacy with toxicity 
screening, and personal genetic tests. This made molecular medicine and medical 
diagnostic test characterised less by treating symptoms and more by looking into the 
fundamental causes of disease with real-time diagnostic tests. Therefore, more rapid, 
real-time and more specific diagnostic tests will make possible for earlier treatment of 
countless maladies.  
Although the cost of the lab-based tests have been reduced dramatically and the tests 
become popular and essential in detection of many infectious disease, the gap is not 
being filled in to improve the turnaround speed and reduce the skill requirement. 
Further reduction of the cost will benefit users in applications which have been priced 
out and are not available. More detailed discussion follows in later chapters.   
It is essential to include DNA sequencing in the discussion of molecular diagnosis. 
The sequencing provides the ultimate information of the genetic makeup of an 
organism, pathogen or host. Any nucleic acid based diagnosis can be considered as a 
reduction of the DNA sequencing technology. The basic principle and chemistry are 
similar between PCR and sequencing, which is enabled by the Watson-Crick base 
pairing nature of nucleic acid [16]. With sequencing technology, thousands to billions 
of nucleic acid sequences could be produced in one assay while one or few bases are 
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revealed by PCR or similar molecular diagnostic assays. The sequencing technology 
today has made a great progress but it still requires very specialised resources and 
discouraging cost to sequence a human genome. It is very difficult to use sequencing 
as a molecular diagnostic tool before the next  major breakthrough in sequencing 
technology. As a solution, assays using relatively simple technologies, such as real-
time PCR, are developed to fill the need.  
With the speed of evolution of sequencing technologies, it should not be long before 
the first diagnostic application using sequencing. It is sensible that the enabling 
technology revolves around ultra-high density sequencing. At the moment, the major 
users of the current next-generation sequencing tools are research laboratories and 
gene-discovery companies for applications such as disease surveillance on dangerous 
mutations, flu virus genomes, mutation disco, linkage study of cystic fibrosis gene, 
and clinical lab for cancer/disease diagnostic or prognosis.   
In October 1990, The Human Genome Project (HGP), formally began its strenuous 
thirteen years of international effort, concluded with a remarkable prominent 
achievement in biochemistry by completing the sequencing of 3 billion DNA subunits 
bases in the human genome [28, 29]. In early 2005, the materialisation of new DNA 
sequencing technologies has dramatically revolutionised the structure of the 
sequencing industry [30, 31]. This was a direct result of the arduous efforts made by 
the consortium, numerous genomics researchers and mostly importantly the emerging 
novel sequencing technologies. This later development allowed for a considerable 
reduction in the cost of the sequencing process in addition to supplying innovative 
and economical platforms for the next-generation of DNA sequencing. The scale of 
reduction of sequencing time and cost is exponential, which is comparable to Moor’s 
law in semiconductor industry [26]. Without using Sanger’s method [32], it is 
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possible now to sequence a whole human genome within days, which costs only tens 
of thousands US dollars [33]. This new generation of technologies and research has 
changed the landscape of DNA sequencing. The technology has become a push force 
that has established a positive feedback ecology between emerging applications [34, 
35] and creation of new markets. As result, new research in DNA sequencing 
technologies will persistently grow[36] and continue to alter the spectrum of the DNA 
sequencing industry as innovative market opportunities arise.   
Current state-of-art sequencing technology depends on synthesis of labelled nucleic 
acid or detection by synthesis. The target molecules could be DNA or RNA. Here we 
present some background knowledge about deoxyribonucleic acid (DNA) and 
ribonucleic acid (RNA) in the first half of this chapter, followed by an overview of 
various sequencing applications by density throughput. Finally, we conclude this 
chapter with an overview of the current sequencing/genotyping technologies.  
2.1 DEOXYRIBONUCLEIC ACID AND RIBONUCLEIC ACID 
Living organisms are complex systems, which are made of cell or cells. It is estimated 
that as many as tens of thousands of different proteins are responsible for the normal 
cell functions [37]. In order to regulate and program such complicated networks of 
proteins, an enormous amount of information is required to be stored and processed 
correctly even in the most complex system.  In this information system, it entails 
specific structures of proteins as well as the regulation instruction of proteins. The 
vast amount of information is coded and stored in the genome, which is made of 
nucleic acids [38].  
The structure of a nucleic acid contains two main parts, ribose phosphate and 
nucleoside. The backbone of a nucleic acid is made of ribose sugar (RNA) or deoxy-
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ribose (DNA) and phosphate connecting nucleic acids in a long chain. Each backbone 
ribose is attached to one of four different nucleoside bases.  The order of the 
nucleoside in a long chain forms the basis of the sequence. The regulation and gene 
information are coded in the sequence. Genomic nucleic acid is mostly 
deoxyribonucleic acid (DNA) except in some virus genes, and are coded in 
ribonucleic acids (RNA). The famous double-helix structure of genomic DNA 
consists of two complimentary strands. Each strand consists of sequence of four 
nucleotide bases, adenine (A), cytosine (C), guanine (G) and thymine (T) as shown in 
Figure 2-1. In the structure of a double-helix, a nucleotide forms a Watson-Crick 
base-pairing relationship with another, such that A is complimentary to T and G to C.  
The double stranded structure is the basis for some crucial functions in life, such as 
replication of the genome, the process of copying itself to form new cells.  
In the process of replication, the double-stranded structure is denatured with the help 
of replication machinery.  Each strand then acts as a ‘template’, on which a new 
strand of nucleic acid grows by adding complementary nucleic acids to the template– 
adenine (A), which can only pair with thymine (T) and cytosine (C) can only pair 
with guanine (G). The process is known as ‘chain extension’ since the nucleic acid 
chain is extended by adding one nucleotide after another. As the chain extends, new 
double-stranded DNA is created consisting of a strand from the existing base template 
and anther strand synthesised based on the template [38]. 
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Figure 2-1: The structure of deoxyribonucleic acid and ribonucleic acid. Reproduced 
from National Human Genome Research Institute. 
Unlike DNA, Ribonucleic acid (RNA) is usually a single-stranded molecule. There is 
hydroxyl group at ribose of RNA, which contributes to higher chemical activity, 
which makes RNA more susceptible to degradation. Another important feature of 
RNA is that thymine of the four nucleoside is replace with uracil. (Figure 2-1) The 
uracil is paired with adenine in Watson-Crick base-pairing.  
RNA plays an important role for the process of producing proteins. The messenger 
RNA, which is a transcription from genomic DNA, has the non-coding region of 
genomic DNA removed. As the result, the sequence of mRNA is more close to the 
sequence of protein following the corresponding codons. Study of the messenger 
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RNA reveals the snap-shot-of activity of the cells or tissues. The expression of the 
messenger RNA provides information as how cells are regulated and response to 
extracellular stimulation as well as the differentiation of tissues. It is also vital as a 
diagnostic tool such as the identification of canner tissue or mechanism of the 
metastasis.  
RNA is also the genomic material in retrovirus, such as influenza virus or HIV virus. 
The understanding and surveillance of the sequence of the RNA has been very 
important in containing the spread of diseases. On the occasion of a new influenza 
event, sequencing the RNA genome is the main methodology in the establishment of 
the nature of the virus.  
2.2 SEQUENCING, MARKETS, AND APPLICATIONS 
2.2.1 SEQUENCING 
Sequencing has become an indispensible method for biological researches as well as 
applied service products. The emerging sequencing technologies developed on the 
shoulder of the capillary-based Sanger method have generated tremendous amount of 
the raw data. These raw data is not very useful without the equal development of bio-
information innovations. The data generated from the new sequencing methods is 
generally highly fragmentised genomic seqeuences. A generalised workflow of 
emerging sequencing technologies contains four steps. First, the nucleic acid (DNA or 
RNA) is been purified and stabilised. The nucleic acid will be randomly fragmentised 
to fit into the size of sequencing length and for some methods enriched by 
amplification in the second step. As a result of the fragmentation, 105-107 of sample 
sequence pieces are generated.  Each sample is then subject to a sequencing step, 
40 | P a g e  
 
where the detection methods are involved. Two classes of detection methods would 
cover most of the current emerging technologies, sequencing by synthesis 
(pyrosequencing, Illumina/Solexa system, and Life Technology Solid system) and 
sequencing by direct reading the nucleoside sequence of a nucleic acid string (Pacific 
Biosciences, Helicos Biosciences and nanopore technologies) [39]. At the end of the 
sequencing step, a large number of the sequences of various lengths, which overlap 
each other, are assembled using bioinformatics methods. The degree of the 
overlapping between sequences generally refers to the coverage of how deep the 
sequencing is. A deep sequencing run can generate the number of nucleoside read 20 
times more than the size of the sample. For example, the 20 times of human genome 
is 6×1010 nucleotide base output.  
2.2.2 MARKET 
Bioinformatics is applied to the large number of the information generated in a 
sequencing run. Genomic samples from different species can be resolved without 
tedious strain isolation in metagenomic studies. Similarly, deep sequencing is 
essential in fields such as epigenetic which plays an important role in cancer 
development, high genetic variation study such as human leukocyte antigen typing, 
and rare virus strain diagnosis in HIV therapy.    
Consequently, the new sequencing methods are transforming the practices and 
enabling sequencing as a tool in clinical diagnostics, biotechnology, forensic biology, 
as well as basic biology. The advent of sequencing technologies and the emergence of 
novel applications have driven the market to grow immensely. The 454 Life Sciences 
sale figure for 2009 is $143 million [40], $80 million for Life Technology SOLid 
system in a CityGroup report [41]. The largest market share is occupied by Illumina, 
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which accounts for 60% of the total market in the same report. According to the 
consulting firm Scientia Advisors, the DNA sequencing market including system 
sales, reagents, and service, is expected to grow from $1.2 billion in 2009 to more 
than $3.6 billion in 2014 [42].  
2.2.3 APPLICATION 
The DNA sequencing market is divided into various segments by application: Life 
science research and drug discovery for further medical and bioscience developments. 
Due to the high cost associated with the current emerging sequencing methods and 
low throughput of capillary methods, the commercial applications are restricted at the 
moment.  
Currently, major sequencing market sales are from biological research project 
founded by government or institutions or Pharma/biotech in the field such as drug 
discovery.  The revenue has an estimated of $920.1 million in 2010.  Within 5 year, 
the markets are expected to increase to $1.7 billion which is equivalent to a compound 
annual growth rate (CAGR) of 13% [43]. 
The sequencing tasks from research project tend to be gene discovery instead of gene 
testing. The genomic sequencing work is still active in more organisms or re-
sequencing form individual variations.  
Some limited applications are molecular diagnosis such as cystic fibrosis, where the 
variation is great. The interest is also increasing in oncology. As tumour is typically 
associated with multiple mutations and auto-mutations, identification of mutation 
components could be useful in making decisions for a specific therapy regime. It is 
one of the personalised medicine applications [44]. 
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One high profile case that is trying to break away from the model is the direct to 
consumer (DTC) personal genome service. This type of model combines the 
technology providers, such as Illumina, and high street shops facing consumers, such 
as 23andme. The customer submits the sample such as saliva to the shop, which 
provides a list of pre-selected sequencing products. The sequencing factory is then 
commissioned to perform the test without knowing the identity of the customer. 
However, the type of service has been under scrutiny from regulatory bodies [45]. 
In a more narrowed field of sequencing, the interest has focused on some single 
nucleotide polymorphisms (SNPs). SNP is a type of common genome sequence 
variation in a population. The variation is typically a change of one nucleotide at a 
position while flanking regions are not changed. The application covers some 
common genetic disorder or variations such as drug adverse response. An example is 
the administration of Warfarin. US Food and Drug Administration (FDA) has advised 
taking a SNP test on VKORC1 and CYP2C9 polymorphism for drug dose decision. 
At the moment, high density sequencing, DNA microarray, and real-time PCR are 
three major technologies used in SNP assays. 
It is expected that much more applications in personal genomics will be delivered in 
the near future. The applications cover SNP detection through complex genome wide 
screening or sequencing. Many applications in this field are yet to be established as a 
standard practice. However, the emerging applications carried most expectation for 
exponential market growth as predicted in the last market report. The emerging 
market value will be 10 times bigger in five years from now (Figure 2-2). 
Other emerging applications include diagnostic sequencing, gene methylation 
analysis, and pathogen subtyping. Before sequencing is a standard routine clinically 
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diagnostic tool, cost and accessibility of the technologies would have to be cost 
effective.  
 
Figure 2-2: The projected grow of sequencing applications[43]. The emerging 
applications are expected to outgrowth the current commercial applications at a CAGR 
rate of more than 100% from 2010 to 2015.  
High growth in the DNA sequencing market is foreseeable in the near future. Driven 
by technologies and market forces, the sequencing industry is shifting away from 
stagnant and declining grounds in sequencing discovery market. Advent of DNA 
sequencing as a premier genetic analysis tool used for existing applications such as de 
novo whole genome sequencing in infectious disease surveillance and entirely new 
applications like epigenetic tag sequencing are significant indication of this booming 
market. 
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2.2.4 HIGH-DENSITY SEQUENCING  
The current sequencing technology development has been driven by the throughput of 
the sequence read per run. Part of the drive is due to the size and complexity of 
genomes. Part of the reason is the cost of the test. Due to constrains of the 
technologies available in preparing sequencing DNA, it is difficult to reduce the 
preparation steps.  Fragmentation and genome wide amplification are essential for 
high quality sequencing data. Currently, there are few available proprietary methods, 
emulsion or bridge PCR, which limit the freedom of operation, let alone the 
preparation time incurred.  In order to make the process cost-effective in terms of cost 
and time, a large throughput of sequencing data is required. This is achieved by using 
a higher density of the reactions and microfluidic cell structures. Cost per mega base 
read (USD/MB) is generally used to estimate the cost of the sequencing run. At the 
moment, the cost could be 2-40 dollar per MB, which is about one hundredth of the 
Sanger method used in HGP project (Table 2-1).  
Because of the cost and technology complexity involved in high density sequencing, 
it is not cost effective to sequence target less than a few mega bases.  On the other 
hand, a lower density or a small target would require different detection technology or 
special markets to keep the method market viable.  
 
USD/MB No. run 
Sanger 2742.9 340000 
454 42.9 234 
Illumina 2.1 40 
Table 2-1: Cost and number of sequencing run of sequencing a human genome [39]. 
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High-density sequencing application is defined as sequencing more than millions of 
base pairs per run. This includes full genome sequencing (Genome-wide de-novo 
sequencing/re-sequencing). The method is usually limited to very low sample 
numbers in exchange for an ultra-high base read. The cost of the sample preparation 
and sequencing reaction are spreading over the enormous size of genome. Even so, 
the reported retail cost for the new Illumina HiSeq2000 will cost 10,000 USD for one 
human genome wide sequencing announced by CEO J. Flatley in Goldman Sachs 
Healthcare Conference in 2010.  
The capability of running deep sequencing makes high density sequencing a useful 
tool in monitoring the event of emerging infectious diseases. The method could detect 
conserved point mutations within samples along with the wild type. It is, therefore, 
cost effective in surveillance of dangerous mutations such as Influenza H1N1.   
The main users in this market would remain research laboratories and biotechnology 
companies because of the high cost associated with the technologies. Current players 
in this market are 454 Life Sciences, Illumina Inc, and ABI Solid Sequencing. The 
average cost of sequencing systems in this market is over half a million USD. 
2.2.5 LOW-MID DENSITY SEQUENCING  
Sequencing is a powerful tool in understanding variations between individual as well 
as phenotype association. It is particular useful in the field of diagnosis, prognosis, or 
clinical study. Giga-bases reading is not required if the target of interest includes a 
few genes. Deep sequencing or coverage of the gene is desirable in finding out the 
variations, especially for highly variable regions.  
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Many researchers are interested in mutation discovery and linkage study such as the 
cystic fibrosis gene with larger sample number or cytochrome P450 variations with a 
number of samples.  The application does not require the same number of base 
reading since the length of gene is much shorter than the genome.  
The copy number of a sequence or a gene can vary and the variation is associated 
with a phenotype. The study is called the copy number variation (CNV). It has been 
associated with autism, schizophrenia, autoimmune, and cancer development [46-48]. 
The genes of interest for CNV study are established and knowledge of the variations 
is available. The needed CNV sequencing throughput is much less than the whole 
genomic discovery [49].    
The works on gene variation or CNV form the basis for a diagnosis market which 
depends on sequencing. Diagnostic sequencing could be very specific to a known 
region of genome. Consequently, the sample preparation could target the sequence of 
interest. The fact that there is no need to randomise the fragmentation is crucial. 
When sequencing a known gene, a typical strategy contains amplification using 
specific primer sets. The primer sets are designed in such a way that they anneal to the 
conserved regions of the genome. The yield of the functional sequencing reactions 
will be much higher than the randomised method. It is also possible to automate the 
process without skilled users.  
2.2.6 GENOTYPING  
Gene variation between individuals or organism can be as small as one nucleotide. 
Single nucleotide variation (SNP) is known to associate with serious drug adverse 
effects or infection response [50, 51].The international effort (SNP consortium) has 
been trying to discover novel SNPs, associate the SNPs to phenotypes, and build 
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haplotype of the variation (HapMap)[52, 53]. A few SNPs are associated with disease 
or drug response phenotype. The rest of the SNPs are called silent SNPs. A non-silent 
SNP could be found at crucial position of protein function or regulation of protein 
expression.  
 
Figure 2-3: Amino acid sequence variation in HLAB57/5801. The variation from 
consensus sequence is shown in the table. The amino acid sequence variation is 
corresponding to gene sequence mutation or SNP [54]. 
For SNP discovery, deep sequencing is a reliable method to find out the variation. 
The users of SNP discovery are mainly research institutes, biotechnology firms or 
pharmaceuticals. On the other end in the genotyping market, the mutation or variation 
is known. The task is to query the sample about its genotype. There are a few methods 
to detect SNP. Since the sequence in query is only one nucleotide, it is possible to use 
a PCR method or a DNA microarray to detect SNPs. Although these methods are 
strictly limited to pre-defined known variation, they can process much higher sample 
numbers. With a typical micro-titre plate assay, it is possible to run many PCR 
reactions using a standard 96-well format at a time. With PCR technology, the 
requirement for sample preparation is much less than any sequencing methods. 
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Therefore, the application of sequencing technology will be limited to highly variable 
regions, such that there are many SNP in a short region of sequence. It is very 
difficult to query multiple variations spreading over a short distance using PCR 
methods. An example is show in Figure 2-3. In the case of GF14 epitope, the three 
variations are within six amino acids, which is equivalent to 18 nucleotides.  
In such a field, direct sequencing is the best method to query the genotype of the 
sample. The low to mid density sequencing methods do not provide the whole picture 
of a genome. However, genetic variations are few and most of the genomic sequences 
are the same between individuals. It is sensible to target the variations that are 
relevant rather than sequence the whole genome. When the application is very 
specific, such as a particular drug response, low-mid density sequencing methods are 
the better tools that provide critical information.   
2.3 CURRENT DNA SEQUENCING/GENOTYPING 
TECHNOLOGIES 
2.3.1 INTRODUCTION 
Innumerable technologies and resources have been promoted by the HGP project with 
profound impacts on biological researches, revolutionizing a wider spectrum of 
biomedical research, and clinical medicine.  
HGP has relied heavily on Sanger sequencing, which is time consuming and 
extremely expensive (Table 2-1). The advanced DNA sequencing technologies have 
resolved such drawbacks. It brings down the sequencing cost dramatically. With the 
introduction of the HiSeq 2000 earlier 2010 [55], the cost of sequencing a full human 
genome had dropped to the $10,000, which is helped by much higher throughput, 
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comparing with the price tag of $48,000 a few years ago. In some cases, where the 
clinical relevance is obvious, the cost of sequencing a human genome can be reduced 
to $9,500. The sequencing service is becoming affordable for mid-small research 
groups or individuals.  
At the moment, the major DNA sequencing technology providers include Illumina 
(Solexa), Life Technology (ABI and Ion Torrent), Roche (454 Biosciences), Pacific 
Bioscience, and Helicos Biosciences. Companies developing the nanopore methods 
for sequencing [56-58] such as Oxford Nanopore Technologies [59, 60] are yet to 
produce commercial products in the market.   
With the challenge of 1000 dollars per human genome, the most promising 
technologies are single molecule sequencing. Rather than reading the signal from 
thousands of pre-amplified molecules, single-molecule sequencing techniques can 
read the signal from a single molecule. The signal could be fluorescent labelled 
nucleotides, such as Pacific Biosciences, or direct reading using electrical signals, 
such as nanopore methods. However, single molecule detection is generally very 
sensitive to background variation. The cost of the sequencing assembly is also a 
challenging bottleneck.  
Here is a short review about the evolution of the sequencing technology in detail.  
2.3.2 1ST GENERATION SEQUENCING 
The first generation sequencing is synonymous to the Sanger method. The method is 
based on the chain terminator reaction. The sequencing start from a purified double-
stranded DNA. Sequencing reaction is divided into four ddNTPs. Newly synthesised 
DNA is labelled by strand ( Figure 2-4) or by ddNTPs. The sequence from a specific 
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primer can be resolved by running on a high resolution denaturing gel [61]. For each 
Sanger run, the sample is split into four terminator reactions, (ddATP, ddGTP, 
ddCTP, and ddTTP). The terminator is a nucleotide analogue which is labelled with a 
fluorescence molecule. When a strand of DNA is incorporated with a terminator, the 
extension reaction is terminated due to the lack of active 3’ hydroxyl group on the 
terminator. In each termination reaction, the extension from a primer will terminated 
at various positions. Once the terminator reactions are finished, each reaction is 
applied to gel electrophoresis.  From the result of the gel read, a sequence can be 
established to around one thousand bases. The work flow is illustrated in Figure 2-4. 
 
Figure 2-4: Work flow of Sanger sequencing method. Reproduced from Northwest 
Fisheies Science Center.  
The method, however, requires large amounts of the fragment in separate reaction 
tubes. This is typically achieved by cloning technology. The genomic DNA has to be 
sheered into millions of fragments, which are transformed into bacteria. Bacteria 
grown in a single colony contains only one type of fragment. Each colony is grown 
51 | P a g e  
 
into larger amount in order to produce enough plasmid, which is purified for Sanger 
sequencing. The process is illustrated in Figure 2-5. The target DNA sequence has to 
be fragmentised and cloned into a bacteria plasmid (bottom left of the graph). One 
bacterial dot grown on an agar plate (bottom right) represents one plasmid or one  
unique fragment of template [62]. 
 
Figure 2-5: Cloning step for Sanger sequencing [62].  
The cloning step has severely increased the complexity of the sequencing method. 
Millions of samples are going through growing bacteria, purification of the plasmid, 
sequencing reaction, and electrophoresis. It is not surprising that it has taken more 
than 10 years to finish a draft map of the human genomic sequence.  
2.3.3 2ND GENERATION SEQUENCING 
The next generation of sequencing methods have tackled the complexity issue in the 
preparation of the DNA sample. The complex cloning system is replaced by in vitro 
amplification methods. The challenge of creating amplified DNA fragments in a 
physically separated space was solved by performing emulsion PCR using micro 
beads. The reaction removes the need for cloning and purification altogether. The 
52 | P a g e  
 
method was pioneered by 454 Life Sciences, and is shown in Figure 2-6. .In an 
emulsion PCR, micro particles and DNA fragments are mixed in a diluted solution 
therefore part of the beads contain only one copy of DNA fragment in the first step. 
Millions of bead in individual oil droplet go through PCR simultaneously in a tube. 
As the result, each template DNA is amplified without contaminating each other 
[63].The genomic DNA is fragmentised by sonication or sheering. After polishing 
both ends of double-stranded DNA fragments, an oligonucleotide adapter is added to 
the fragment. The adapter will guide the DNA template to anneal with a primer on a 
microbead. When the solution of microbead and DNA template is diluted, according 
the Poisson distribution, fraction of the beads will only have one DNA template per 
bead.  
 
Figure 2-6: Work flow of emulsion PCR [63]. 
The ability of amplifying the genomic fragment in a single tube reduces the 
preparation time from weeks to a few hours. The cost saving is more than thousands 
fold as there is no need for growth media and colony management. As there is only 
one type of DNA template in each bead, the sequencing reaction at each bead 
represents a full sequencing of one Sanger’s gel.  
53 | P a g e  
 
2.3.3.1 454 TECHNOLGOY 
454 Life Science [30] published the first sequence map of genome in 2005 using a 
pyrosequencing method. The work-flow of the 454 sequencing system FLX contains 
the preparation of the DNA bead by emulsion PCR, loading the bead in the micro-
wells, sequencing by synthesis in each well, and base-calling with sequence assembly. 
Nucleotide of A, T, G, and C flow through the bead sequentially. The reaction 
chemistry is based on the product from the DNA extension, pyrophosphate. 
Pyrophosphate is used to as the energy source to drive light emission by luciferase as 
shown in Figure 2-7. The emission is proportional to the number of nucleotide 
extended, therefore multiple insertions of a single nucleotide can be resolved. The 
density of the 454 micro-well is about 400,000 per chip. However, the yield of read 
from the chip is about 50% due to multiple-bead in a well or empty bead without 
DNA template. The light emission is detected by optical detector through the optical 
fibre. The read throughput is restricted by the number of active beads per chip times 
the number of read length, which is about 400-800 bps.  
 
Figure 2-7: 454 pyrosequencing reaction mechanism. There are three types of 
microbead in 454’s system. The largest one is the DNA beads. The enzymes and 
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polymerase is immobilised to other beads such that the assembly can go through many 
cycle of washing [64]. 
2.3.4  SOLEXA TECHNOLOGY (ILLUMINA)  
The cumbersome step of cloning in Sanger sequencing is replaced by the polony 
method in Solexa Technology. The polony is defined as the DNA colony on a solid 
matrix in comparison to the bacterial colony on an agar plate. Solexa achieved the 
polony by performing bridge PCR on a micro slide as shown in Figure 2-8. The 
sequencing reaction is similar to Sanger method but the terminator could be activated. 
Each terminator (A, T, G, and C) carries a unique fluorescent label. Photos of four 
colours are taken and each colour represents an insertion of the corresponding 
nucleotide.  
After the reading is done, the blocker at the 3′  end of the inserted nucleotide is 
removed and the next round of terminators is introduced. Repeating the process builds 
the sequence of the target template.  
The method can achieve very high density since the DNA cluster occupies a much 
smaller space (10-100 nm pitch distance) than a micro-well does. As the result, much 
larger data throughput, 100 million polonies per chip, is possible with the method.  
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Figure 2-8: Solexa bridge PCR mechanism. Each fragment of DNA template is 
amplified and forms a small cluster on the surface of the chip, called polony [39]. 
2.3.5 HIGH DENSITY 3RD GENERATION SEQUENCING TECHNOLOGIES 
Numerous sequencing technologies have emerged from companies such as Pacific 
Biosciences, Oxford Nanopore, Cracker Bio. However, these sequencing technologies 
either require optical labelled detectors with very high resolution/speed or the difficult 
to control pore detection at the current state-of-art setup. Many disadvantages then 
may be, but high hope has been that the technologies could one day remove the need 
for enzyme reactions used in pyrosequencing or amplification. It is still early in term 
of maturity of technology but single molecule detection has shown the potential for 
very long read (> 1,000 bases) and capability of reading the methylation of the 
nucleotide in CpG islands.  
Oxford Nanopore Technologies and others are developing a new generation of DNA 
sequencing technology that does not require fluorescent labels or optical 
instrumentation. The method reads DNA bases directly. The measurement is possible 
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by passing a strand of DNA through a very small hole. Signals of different bases are 
differentiated and recorded in sequence as the strands of DNA moving through the 
nano pores.   
2.3.6 LOW DENSITY GENE SPECIFIC GENOTYPING TECHNOLOGIES 
The genotyping is the process of determining the genotype of an individual by the use 
of DNA micro arrays (Figure 2-10) or real-time PCR (Figure 2-9). Due to current 
technological limitations, the sequencing result from genotyping is partial even with 
the ultra-high density of DNA microarray. However, clinical relevant sequence 
information generally is very concentrated in short regions since the protein-encoded 
sequence only accounts for less than 2% of the total genome [65]. Sequencing by 
microarray or real-time PCR could be effective when the sequence variation is very 
well known and conserved. However, for de novo sequencing or sequence variation 
discovery, it is better to use high-density sequencing method or Sanger’s method.   
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Figure 2-9: SNP detection using Tagman assay. The SNP in the graph is CYP2C9. In the 
bottom graphs, it contains several samples in each graph. The black lines represent the 
homozygotes while the pink lines in the middle represent heterozygotes [66].  
Genotyping covers copy number variation (CNV), SNP, deletion and insertion of 
gene sequence. The new knowledge of epigenetic application will cover the 
methylation of the genome sequence [67]. It is also very useful in typing and 
identifying infectious diseases. Viruses for instance, or bacteria, can be detected 
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and genotyped for great clinical value [68]. Genotyping in this context may help 
in controlling the spreading of pathogens, by tracing the origin of outbreaks. This 
area is often referred to as molecular epidemiology or forensic microbiology. 
 
Figure 2-10: The DNA microarray [69] 
Apart from pharmacogenetics applications in genotyping human beings, the 
technology is also crucial in individual identification, When testing for father-
/motherhood for instance, scientists typically only need to look at 10 or 20 genomic 
regions (like single-nucleotide polymorphism (SNPs) to determine relationship or 
lack thereof. That is a tiny fraction of the human genome, which consists of three 
billion or so nucleotides. 
Genotyping mainly focuses on molecular diagnostic, genome-wide SNP pattern 
discovery, direct-to-consumer (DTC) personal genetic tests such as 23andme and 
Navigenetics. 
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2.4 SUMMARY  
DNA sequencing technologies continues to be currently dominated by the Sanger 
chain termination method. Motivation for faster, simpler technologies, which can 
sequence genomes within a day, are actively sought and many new techniques to rival 
the Sanger technique are emerging.  
Nucleic acid tests (NAT) have a wide range of applications and markets. They can 
detect the presence of a few copies of cellular, bacterial, or viral genome and with a 
specificity that is capable of detecting a single base change in the nucleic acid 
sequence. The existing applications in the market include the detection of single-
nucleotide polymorphisms (SNPs), human genomic variations, viral and bacterial 
detection and sub-typing.  However, to date the current NAT systems require 
intensive capital investments, complex laboratory based machines, and trained 
laboratory technicians. We are starting to see a divergence in sequencing 
technologies, as each sequencing methods concentrates on having clearly defined 
advantages and potential applications that differ from all others. 
In order to develop a point-of-care setting NAT device, a label free detection platform 
is inevitable. We propose a novel approach based on our core invention. This 
approach utilizes the fact that during the amplification of microbial nucleic acid by 
PCR, where there is an exponential release of protons resulting in a pH change, which 
can be detected using an Ion Sensitive Effect Transistors (ISFETs).   
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CHAPTER 3 – ISFET-BASED NUCLEIC ACID 
REACTION DETECTION  
3.1 PROTON RELEASE MECHANISM 
Nucleic acid detection by ISFET depends on the proton release from a nucleic acid 
reaction. The proton balance after the hydrolysis of a nucleic acid is dependent on the 
dissociation constants of acid and base species in the solution. The production of 
proton causes change of pH, which could be detected by ISFET. The Henderson–
Hasselbalch equation derives pH from the acidity in biological and chemical systems 
as shown in Equation 3-1. [57] The equation is used to find the equilibrium pH in 
acid-base reactions and estimates the pH of a buffer solution. Equations are shown 
below: 
Equation 3-1 Henderson Hasselbalch Equation 
@A = @>1 + log BC
DE
BACE 
Equation 3-2  Equilibrium Constant 
>1 = BC
DEBAFE
BACE  
where @>1 = − logH>1I, and >1 is the acid dissociation constant for the non-specific 
Bronsted acid-base reaction. In addition, in Equation 3-2, CD	represents the ionic form 
of the relevant acid, and [HA] and [H+] are the molar concentration of the quantity 
within the solution.  
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According to the Henderson-Hasselbalch, the pH of a solution containing an acid-
base conjugate pair can be calculated. Thus, the number of protons release is 
contingent to the acid-base equilibrium after the reaction. Essentially, when the 
protons generated pass the buffer capacity, the pH will drop to a new acid-based 
chemical equilibrium.  [58] 
Here are two example cases: 
Case 1 
The initial chemical equilibrium is established at @AJ therefore  
@AJ = @>1 + log BKLEMBNKEM 	OP	>1 = BK
LEMBNQEM
BNKEM      (1) 
Also, from the mass balance,  
BACERSR13 = BACEJ + BCDEJ        (2) 
This is useful since the actual concentration at a given time is difficult to know. We 
know at least two things, (i) boundary condition (starting concentration) and (ii) one 
of the components in real time measurement. (BAFE in this case) We can work out the 
rest components by applying the mass balance and the equilibrium equations.  
When one adds more BCDE salt, such as T1C, the equilibrium balance is disrupted and 
new balance will be reached to maintain a constant Ka. At the new equilibrium, some 
of the BCDE will be removed by forming complex with BAFE.  Here we do not know 
the final BCDE after adding the knownBT1CE1. We can measure the pH value. If the pH 
=	@A6, then  
@A6 = @>1 + log BKLEUBNKEU 	OP	VW	XO	YWZ	ZℎW	\]^W	_`	 BK
LEU
BNKEU  (3) 
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The final concentration of BCDE6 and  BACE6 can be work out using mass balance, 
where 
BHAERSR13 = BACEJ + BCJE       (4) 
BHAERSR13 + BTCE1 = BACE6 + BCDE6     (5) 
Case 2 
The same initial equilibrium was established. This time, we add more alkaline (TcA) 
in with the pH meter recording the reading in real time. Adding the alkaline also 
disrupt the old equilibrium. When the new equilibrium reached, with the help of pH 
meter, you should know the pH value in real time. Let’s assume it is @Ad. 
Again we can use the Henderson Hasselbalch equation to work out the ratio of BCDEd 
and BACEd since the >1 is a constant. That is to say,  
log BKLEeBNKEe = @Ad − @>1      (6) 
From the mass balance, we know  
BHAERSR13 = BACEd + BCDEd      (7) 
In the end, you can find out the concentration of the BACE andBCDE 
Since the reaction is only depending on the nucleic acid reaction. It is plausible to 
extend a single base insertion to continuous multiple-base reactions, such as the case 
in DNA and RNA amplification. Because there is no required modification in the 
reaction mixture, the application is a truly label-free detection of nucleic acid. 
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3.2 DNA AMPLIFICAION BY POLYMERASE CHAIN REACTION 
(PCR) 
The Polymerase Chain Reaction (PCR) was first introduced in 1984 for replication 
and amplification a fragment of double-stranded dsDNA from a given DNA template. 
Typical components of a PCR include: [70] 
1. Thermal cycling temperatures between 98-50⁰C  
2. Nucleic acid template as few as 1 copy  
3. Two oligonucleotides acting as sense and antisense primer and dNTPs  
4. Potassium chloride for stabilization of dsDNA as well as ionic strength  
5. Thermal stable DNA polymerase such as Taq polymerase  
6. Magnesium ion for Taq polymerase activity.    
PCR selectively amplifies a region of dsDNA to a typical 1x108 fold in 35 cycles of 
thermal cycling. The time needed for 35 cycles range from 10 minutes to 2 hours 
depending on the thermal mass of all materials in thermal cycling. When 
diffusion/activity is not considered, the amplification is exponential of 2n, where n is 
the cycle number. In practice, the efficiency is less than one and therefore the fold of 
amplification will be less than 1.7n. As the rule of nature, it is impossible to amplify 
anything indefinitely. The possible restrictions on PCR amplification include the 
increased concentration of pyrophosphate and decayed enzyme activity. [71] 
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3.2.1 INTRODUCTION TO NUCLEIC ACID LABEL-FREE DETECTION 
We use PCR for two purposes, selective amplification for Klenow fragment extension 
and nucleotides detection in the integrated device. Klenow fragment is a DNA 
polymerase, which works at 37f. The name comes from the Danish scientist, H. 
Klenow, who published the method of making the polymerase from E. coli DNA 
polymerase. The size of the Klenow fragment is about 70 kDa with dimension around 
7nm x 8nm x 9nm Figure 3-1. It has one reactive –SH group on the surface, which 
may be able to form a covalent bond with pure gold. [69] 
 
Figure 3-1 3-D structure of Klenow fragment.  
To implement a Klenow fragment extension we must first use a pair of ssDNA 
primers to amplify both nucleotide variations in a targeted location. It is the detection 
ssDNA probe in the Klenow Fragment extension assay that differentiates and gives 
the signal if there is a match. An alternative method involves using a modified primer 
in the ssDNA primer set. The 3'-end of the modified primer matches with the targeted 
nucleotide and forms mis-pair with another nucleotide. Taq, like Klenow fragment, 
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which lacks of 3'-5' exonuclease activity, extends only the matched primer. Only the 
matched nucleotides are amplified exponentially when both primers match with the 
sample. The mismatched nucleotides are also amplified but the amplification is linear 
to the cycle numbers. [24, 72] 
3.2.2 DNA POLYMERASE ACTIVITY: 
The principle of nucleic acid detection relies on the function of DNA polymerases. 
DNA polymerases are responsible for matching DNA sequences with the right 
nucleotides and for catalysing the insertion of the nucleotides on a growing DNA 
primer. Below is a list of critical activities and observations that are important to the 
DNA Logic detection.   
1. 3'OH extension from a ssDNA primer hybridized to a longer ssDNA template.   
2. The activity is dependent on gYdF and use dNTP as the substrates. gYdF is know 
to affect the non-specific extension from a mis-matched 3'OH ssDNA. 
3. The KF should only extend matched 3'OH primer-template duplex but we have 
seen non-specific extension from a mis-matched 3'OH ssDNA. 
4. The pH tolerance is believed to be between pH6 and pH9.  
5. The stamina of KF is low (processivity) at around 100bps before it stops extending 
and dissociated from the dsDNA. 
Taq DNA polymerase which has polymerisation activity extends the ssDNA primer 
from the 3’-OH. The enzyme is relatively stable at high temperature less than 100⁰C. 
There are varieties of Taq polymerase. Most of them are modified chemically or with 
antibody blockage to reduce the activity at room temperature. The blockage can be 
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removed via an activation step normally held at 95⁰C for a few minutes before the 
cycling programme. Each cycle comprises denaturation, annealing and extension. The 
cycle is repeated 30-40 times in a PCR reaction. Each of the three steps has a different 
temperature which is utilised to control the association of polymerases and dsDNA as 
well as the hybridisation of ssDNA. It is possible to merge the annealing and 
extension in one step, which reduces the total reaction time required to finish 
amplification.  Below is a list of important observations and factors that are specific to 
a PCR reaction.  
1. Extension from the 3’-end hydroxyl group of an ssDNA primer hybridized to a 
longer ssDNA template.  
2. Magnesium ion is essential for activity. Typical concentration is between 1.5mM to 
2mM on top of the gYdF-dNTP complex.  
3. Higher magnesium ion concentration increases the activity but also increase 
likelihood of non-specific amplification.  
4. The processivity is at hundreds bps and reaction speed is about 1 kbps per second.  
5. We have seen not difference in amplification between pH8 and pH6.  
1.1 RNA AMPLIFICATION 
Reverse Transcription Polymerase Chain Reaction (RT-PCR) is the reverse 
transcriptase where RNA is reverse transcribed to cDNA using a reverse transcriptase 
and primers. This is an important step allowing the performance of PCR since DNA 
polymerase can act only on DNA templates [73].   
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In the initial phase of the reaction reverse transcriptase (RT) converts the RNA to 
double stranded DNA as in RT-PCR Figure 3-2. 
 
Figure 3-2 RT: Converts RNA to dsDNA 
Subsequently the cDNA is cycled between RNA and DNA in an isothermal process 
Figure 3-3.  
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Figure 3-3 cDNA cycled between RNA and DNA in an isothermal process 
The reactions above take place in a single process resulting in one million fold 
amplification in 60 minutes.  [74] 
1.2 FROM DNA TO PH DETECTION 
Polymerase chain reaction (PCR) is the process of replication and amplification of a 
fragment dsDNA from a given dsDNA template. In the process, dsDNA is denatured 
into ssDNA. Once the melting process is completed, dNTP, DNA polymerase and 
magnesium ion will do the annealing and the extension to the melted ssDNA to form 
a new strain of identical dsDNA.  
Equation 3-3 Protol reaction from nucleic acid extenion 
 
1i
DNA Polymerase
n n
Pyrophosphate
dNTP DNA PP DNA xH +++ → + +  
Klenow Fragment extension (Figure 3-4 and Figure 3-5), also called exponential 
amplification of nucleic acid, follows the same procedure as PCR but given a strain of 
targeted ssDNA primer. In other words, when the target primer matches the sample 
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fragment ssDNA, the fragment will extend while releasing protons and will not 
otherwise Equation 3-3.  
 
Figure 3-4 Klenow Fragment extension – matching – proton release 
 
Figure 3-5 Klenow Fragment extension – mismatch with no proton release 
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1.3 ION SENSITIVE FIELD EFFECT TRANSISTORS REACTION 
MONITORING 
1.3.1 CONCEPTS 
 
Figure 3-6 pH-ISFET scheme by Bergveld 
The ISFET is a device that has gained much attention for use as a pH sensor. Being 
robust, cheap and small in size, it has rapidly become competitive with conventional 
ion selective glass electrodes. The device, which is well described in the literature [25, 
75, 76], consists of a transistor similar to a traditional MOSFET but with the insulator 
surface exposed to an electrolyte solution to form an ion-sensitive area, and a remote 
gate provided by a reference electrode. The rest of the transistor is encapsulated to 
isolate the device from the electrolyte. The sensitivity is explained partly by the site 
binding theory and also by a fast dynamic electrochemical exchange component 
occurring at the surface of the ISFET [75]. The equilibrium between the binding and 
unbinding of charged ions at the gate surface becomes a function of analyte 
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concentration, which is measured as a change in the voltage drop across the 
electrolyte/insulator layers. This change in voltage is often described as a change in 
ISFET threshold voltage [25, 75] or alternatively as an intermediate, pH-dependent 
chemical potential between insulators surface and reference electrode [76] as 
illustrated schematically in Figure 3-7. 
In the past, the ISFET has been prone to problems of hysteresis and drift. Therefore, 
there has been a reluctance to use it in critical biomedical applications. However, the 
method proposed in [77] made ISFET applicable. Changes between insertion and 
non-insertion of nucleotides are always compared such that the measurement of 
absolute pH values is not necessary. We expect the pH change from insertion reaction 
should be proportional to the number of insertions. Absolute measurement is not 
required when the relative difference between insertion and non-insertion is enough 
for monitoring. The use of the ISFET in this manner is considered as a novel method 
of applying the sensor for DNA analysis.  
An ISFET pH detection mechanism for nucleotide incorporation creates a possibility 
of incorporating the detection method into existing cyclic array sequencing 
technologies such as pyrosequencing, allowing procedural simplification and cost 
reductions by eliminating the need for luminescence, fluorescence, and 
electrophoresis [77]. Thus, this particular method permits SNP detection outside 
mainstream laboratory facilities and allows identification by individuals such as 
clinicians and consumers in a point of care setting. 
When chemical reactions cause discrete changes in chemical concentrations, these 
changes can be used as an indication for the presence of a reaction. For example, the 
sequencing of individual base pairs in a strand of DNA due to nucleotide 
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incorporation may cause a change in pH. Detecting this change in reaction serves as a 
positive marker for that nucleotide; therefore confirming its presence in that strand of 
DNA. The ISFET is based on a MOSFET with a remote gate (reference electrode) 
exposing with a chemically sensitive insulator to an electrolyte. Field-effects from 
ionic charge interaction at the insulator surface of an ISFET causes shifts in the 
ISFET ID -VGS  characteristic. The insulator in contact with the electrolyte is chosen 
according to its chemical properties and sensitivity to a particular ion. For the pH-
ISFETs dealt in this thesis, use of silicon nitride and aluminium oxide membranes are 
common [25, 75, 76]. 
Any voltage applied to the reference electrode is coupled via the electrolyte to the 
insulator surface, where a pH-dependent charge from ions on this interface modulates 
the channel current, causing the observed shifts in the ISFET transfer characteristic, 
thus modulating its threshold voltage Vth .  
Equation 3-4 Threshold voltage of ISFET [72] 
hRiHjklmnI = o<pq +r3st − HrS − uSI − v00 +vkwxyz − 2{q +
{k| = hRiH}ykI + h~i 
Equation 3-5 ISFET sensing and surface potential 
h~i = o<pq + {3st − HrS − uSI − {|  
Vchem is a grouping of chemical potentials at the insulator surface of which ϕeo is the 
only pH-dependent term: 
Equation 3-6 
φS = 2.3nH@A28~ − @AI       
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UT  is the thermal voltage kT q , pH pzc  the pH required for zero charge on the 
insulator surface and α  a dimensionless sensitivity parameter representing the 
ISFET’s sensitivity S relative to the ideal Nernstian sensitivity: 
Equation 3-7 Sensitivity of ISFET 
α = p0R  
The dependence of Vchem  on pH is modelled using a combination of the site-binding 
theory and the Gouy–Chapman–Stern double-layer model [78], which can be 
reconciled in a behavioral macro-model representation such as that of Martinoia et al. 
as shown in Figure 3-7. 
 
Figure 3-7 ISFET behavioural macro-model 
A final simplification of this model is to group all chemical potentials independent of 
pH by substituting Equation 3-6 and Equation 3-7into Equation 3-4 and Equation 3-5  
giving: 
Equation 3-8 
h~i =  + 2.3n@A     
where γ is a pH-independent grouping of chemical potentials. With α taken as 
constant to a first-order approximation, the threshold voltage of the ISFET is linearly 
proportional to pH, but is strongly temperature dependent due to scaling by the 
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thermal voltage. [76, 79] It is this change in pH representing in a change in transistor 
threshold voltage which gives rise to a change in the transistor’s drain current. The 
device as with the normal MOSFET can operate in either strong or weak inversion. 
1.3.2 WEAK-INVERSION ISFETS 
The weak inversion region of a MOSFET is a region of operation of the transistor for 
which VGS < Vth  and diffusion of charge carriers rather than drift across an electric 
field dominates the channel current. The large-signal equation for drain current in a 
MOSFET biased in the weak inversion region is given by: 
Equation 3-9 Drain current in weak inversion region [74] 
 = JW 1 − WD  = 2OndW
LM WHD6I  1 − WD  
where β = KW L , VT0  is the threshold voltage for VBS = 0  and n is the sub-threshold 
slope factor and saturation is assumed for VDS > 4UT . It is suggested that this 
equation also holds for a weakly inverted ISFET, since all additional chemical 
phenomena are represented as the modulation of its threshold voltage by the 
potential	h~i , which is linearly proportional to pH. The significance of operating 
the ISFET in weak-inversion is not only the low current and voltages involved, but 
also that since the drain current of the ISFET is exponentially related to its threshold 
voltage which is proportional to pH, and pH is in turn logarithmically related to 
hydrogen ion concentration, a direct relation between drain current and hydrogen ion 
concentration will be apparent. [76, 79] A pH fluctuation, pH can be seen to scale the 
current as follows from Equation 3-4, Equation 3-5 and Equation 3-7: 
∆hnJ∆h~i = 2.3n∆@A        (8) 
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From Equation 3-9, with VBS = 0  and assuming saturation (VDS > 4UT ): 
HhnJ + ∆hnJI = 2OndW
WL∆M  = W
Le.∆ ¡ 
 (9) 
Finally substituting in the logarithmic dependence of pH on hydrogen ion 
concentration: 
Equation 3-10 Definition of pH value 
@A = − log6JBAFE 
Equation 3-11 Drain current and proton concentration 
HhnJ + ∆hnJI = WDd.7¢HD £¤ ∆
BNQE d.7⁄  = ∆BAFE¢ ⁄  
This shows that the quiescent drain current IDQ  in a weak inversion ISFET that is 
scaled by a known and temperature independent power of a change in hydrogen ion 
concentration. This is a significant result, which could be manipulated into a more 
useful linear relationship. The index (α/n) of BAFE will always be between 0 and 1 
since 0 < α < 1 and n > 1. To achieve direct proportionality between BAFE and drain 
current, ∆VTH can be amplified by a gain A such that αA/n = 1 before converting it to 
a current. 
Alternatively, using a chemically tailored pH sensitivity such that α/n=1/x (where x is 
real), the drain current can be raised to a power x using simple trans-linear circuits. 
The latter method is presented herein because it is a large-signal approach and 
therefore operable over a wide pH range. 
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1.4 SIMULATION RESULTS  
This simulation presents an output of an ISFET when there is a pH change. Here we 
assume a reverse transcription with RNA to form DNA such that DNA is the only 
input. The simulation does not include the boundary condition that the reagent will 
deplete in the end of the reaction. It only shows a general trend of the pH value trace.  
 
Figure 3-8 Simulation results - pH drop after reaction. The pH decreases rapidly when 
there is enough amplicon accumulated between 20 and 30 cycles. 
The simulation demonstrated pH response in a PCR reaction. The condition used in 
the simulation is 0.1pM template concentration, 300 base-paired amplicon, and the 
amplification efficiency coefficient 0.7 in each doubling of PCR cycle. As shown in  
The result above proves the theory that ISFETs can be switched on when protons are 
released from primers extension.  
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1.5 SUMMARY 
In this chapter, we have demonstrated the theoretical basis for the chemistry as well as 
the ISFET responses. By monitoring the pH change of a nucleic acid reaction and 
comparing with a control experiment, it is possible to monitor the reaction. The 
integration of the reaction chemistry and ISFET sensor would enable a true lab-in-a-
chip format of biosensor.  
Building on the simple method of a single extension using ISFET, one can increase 
the density of the reaction drastically using standard CMOS process, which could be 
applied to ultra-high throughput sequencing. The leverage of the CMOS sensor 
technology also applies to POC, where critical information of pathogen infection 
could be identified by ISFET-dependent nucleic-acid amplification monitoring.  
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CHAPTER 4  – DNA LOGIC  
4.1 INTRODUCTION 
The feasibility of digital computation in cells has always attracted much interest. 
Attempts have been creating in-vivo digital logic circuits using DNA binding 
Proteins, and gene expression has gained much interest. [80]. Our method should 
permit numerous improvements for nucleic acid testing outside of mainstream 
laboratory facilities and allow identification by individuals such as clinicians and 
consumers in a point of care setting. 
Similar to the process that electronic microprocessors to control electromechanical 
devices, biochemical reactions can be used as biochemical circuits to control discrete 
electrical events. Although the construction of these circuits has been explored 
theoretically since the birth of molecular biology, current practical implementations of 
reaction changes due matching biochemical events has led to the creation of 
chemical-logic circuits. This chapter proposes a novel method of DNA Logic, a 
subset of chemical-logic, using silicon based transistors with chemical interactions to 
create so called DNA switches that may perform in-vitro computation. 
4.2 DNA LOGIC THEORY  
The pH detection of CMOS ISFET is possible because of the pH sensing capability of 
the CMOS passivation layer, which happens to be silicon nitride. In order to create 
ISFETs in unmodified CMOS, the standard MOSFET from the technology is used 
with an extended floating gate to the passivation in order to sense ionic changes on 
the insulator. Because it is one and the same with the MOSFET, integration of 
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ISFET/MOSFET pairs is possible to create highly monolithic chemical sensing 
systems. In addition to this the decreasing feature size of the transistor according to 
Mores law, allows implementation of miniaturized ISFETs, which can be combined to 
form large-scale arrays for parallel biochemical processing.  
When chemical reactions cause discrete changes in chemical concentrations, these 
changes can be used as an indication for the presence of a reaction. For example, the 
sequencing of individual base pairs in a strand of DNA due to nucleotide 
incorporation may cause a change in pH [77]. Detecting this change in reaction serves 
as a positive marker for that nucleotide; therefore confirming its presence in that 
strand of DNA.  
 
Figure 4-1 Reaction monitoring of a base pair match and mismatch 
Figure 4-1 shows an example whereby we can see the reaction due to a matching 
nucleotide using the protocols described in [77]. The reaction is measured with an 
ISFET, whereby the decrease in source voltage indicates a decrease in pH. Assuming 
reaction took place at a pH of 7.8, and assuming near Nernstian sensitivity of 50mV, 
the change of 25mV results in a 0.5 pH change. By setting a threshold just above the 
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mismatch voltage, this reaction can be simplified as a chemical logic boolean 0-1 
result which can confirm the presence of a match. An aggregation of all these results 
could then be used to sequence the genome using conventional combinatorial digital 
logic functions. 
The operation of the ISFET as a means of implementing a “DNA logic” unit capable 
of calculating truth-table type outputs is an attractive idea for array-based algorithmic 
processing. The sooner the conversion to digital 0 or 1 signals, the less the effect of 
degradation from interconnects and sources of interference between the sensor chip 
and any off-chip interfacing. 
To demonstrate how aptly ISFETs can be used for this type of operation, we present 
an adaptation of the standard CMOS inverter, Figure 4-2(a), which performs a pH 
thresholding operation when one of the MOSFETs is replaced by an ISFET, Figure 
4-2(b). The circuit can be implemented in strong or weak inversion, but for low power 
operation, the analysis herein is restricted to weak inversion.  
 
Figure 4-2(A) Standard CMOS inverter and (B) ISFET-based inverter OR “pH 
thresholder” 
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Figure 4-3 SIMULATED   	VERSUS  AT PH 6, 7, 8 
The standard CMOS inverter in weak inversion has the transfer characteristic shown 
Figure 4-3. At the switching threshold h	Rℎ, M1 and M2 have equal drain currents 
giving: 
Equation 4-1 
h	Rℎ =
h − ¦hny2¦ + ln 002hny
1 % ln 002
 
where the sub-threshold slope for NMOS and PMOS are assumed equal. We have 
already seen from a behavioural point of view that the ISFET can be considered to be 
a MOSFET with a chemically sensitive threshold voltage, where h~ℎ  varies 
approximately 55mV/pH [74]. Therefore, if the NMOS in Figure 4-2(a) is replaced 
with by an n-channel ISFET as shown in Figure 4-2(b), the switching threshold will 
be given as [81]: 
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Equation 4-2 
h	Rℎ =
h − ¦hny2¦ + ln 002 Bhny + h~ℎE
1 + ln 002
 
4.3 SIMULATION RESULTS 
The simulated transfer characteristic of the ISFET-based inverter circuit Figure 4-2(b) 
in buffer solutions of pH 6, 7 and 8, is shown in Figure 4-3. The circuit was simulated 
in the UMC 0.25µm CMOS technology,	h§§  = 2.5V, using a simplified version of the 
Martinoia macro-model [78] with perfectly linear pH sensitivity (constant α for all pH 
and temperature). Device dimensions were 50/50 for n-type ISFET X1 and 50/10 for 
p-type MOSFET M2. 
 
pH 3 4 5 6 7 8 9 10 
Vinth(V) 1.148 1.176 1.204 1.231 1.258 1.286 1.31 1.341 
Table 4-1Effect of pH on switching threshold 
The effect of pH on the switching threshold is shown in Table 4-1 and illustrated in 
Figure 4-3. A consequence of this characteristic is that if  V¨¤
 
is fixed, then switching 
will occur exclusively due to a change in pH. Moreover, the pH threshold at which 
this switching occurs can be set by our choice of V¨
 
as shown in Figure 4-4. For 
illustration, it is shown that the output is high for pH ≥ 4 when V¨¤
 
is fixed at 1.18V 
and for pH 8 when V¨¤ =1.26V. 
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Figure 4-4 SIMULATED PH SWITCHING THRESHOLDS FOR DIFFERENT INPUT BIAS 
VOLTAGES 
The significance of this simple circuit is that it is a type of pH comparator, not 
switched by a 0 or 1 on the gate input, but by a pH less than or greater than a chosen 
threshold. Simulation results have shown the uncertainty region around the threshold 
pH to be approximately ±0.3 pH units. This is nevertheless a potentially useful 
technique for array-based thresholding operations where trends and not accuracy are 
the focus. Discrete pH changes caused by events such as primer extension for Single 
Nucleotide Polymorphism (SNP) detection extend “pH thresholding” to “DNA logic”, 
which has a practical utility in the direct transduction of a DNA input to a binary 
output as shown in Table 4-2. Figure 4-7 shows circuit simulations showing how the 
measured data from nucleotide incorporation would be converted to a digital output 
by the ISFET-based DNA logic “NOT” gate in Figure 4-2. 
pH < pHth DNA Input Output 
0 mismatch 1 
1 match 0 
Table 4-2 Truth Table of DNA Logic “NOT” Gate 
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4.4 DNA LOGIC CHIP 
4.4.1 MEASURED RESULTS 
This section presents the measurements of the DNA logic chip. This unmodified 
CMOS ISFET chip was fabricated with AMS 0.35 µm  technologies, containing four 
invertors in each corner for protons detection, Figure 4-6 and Figure 4-5 shows the 
layout of an inverter on the chip with p-type MOSFET and n-type ISFET, which is 
the same layout shown in Figure 4-2. 
 
Figure 4-5  World first DNA Logic Inverter with p-type MOSFET and n-type ISFET[82] 
Figure 4-7 shows the DNA logic inverter are pH sensitive, however the switching 
transient is about 1V. With the result, we can conclude an indication of a working 
inverter with an unmodified CMOS ISFET. 
In addition, switching transient of 1V is an issue in practice. Normally in a point of 
care (POA) setting, the amount of sample input is often not enough to trigger the 
switching mechanism of an inverter. Thus, to resolve this problem, we propose a 
circuit solution by employing feedback to a programmable gate ion sensitive field 
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effect transistor’s (PG-ISFET) electrical gate such that switching the transistor can be 
achieved for changes in pH as low as 0.1 units.  
 
 
Figure 4-6 CMOS ISFET CHIP WITH FOUR ISFET INVERTERS 
 
Figure 4-7 Data Results  versus  at pH 4, 7, 9 
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4.4.2 PG-ISFET BASED CHEMICAL LOGIC FOR REACTION MONITORING 
This section presents the use of a Programmable Gate -Ion Sensitive Field Effect 
Transistors (PG-ISFET) to form chemical-logic gates for reaction monitoring. A PG-
ISFET sensor is integrated with standard MOSFETs to form a chemical-inverter, 
which switches when a chemical reaction reaches a certain threshold. By employing 
positive feedback to the electrical gate, switching is achieved for changes in pH as 
low as 0.1 units. Using this, chemical-logic arrays can be synthesized to carry out 
highly parallel chemical processing functions for applications such as DNA 
sequencing. 
Implemented in typical 0.35 µm technology, this implementation overcomes the 
limitations imposed on standard chemical logic inverters due to implementation in 
CMOS [82]. As a result, it can be used to digitize changes in reaction, which allows 
parallel combinational logic functions to be implemented, giving high throughput and 
instantaneous results from large-scale arrays. 
In order for a chemical logic signal to be derived, a change in pH needs to be 
converted to a discrete value. In [82]a simple ISFET/MOSFET inverter shown in 
Figure 4-8 was proposed which could cause switching due to a change in pH. When 
implementing ISFETs in unmodified CMOS however, the voltage on the floating gate 
of the ISFET is divided down due to the passivation capacitance, which exists due to 
Si 3N 4  passivation [83]. The result is that a larger pH swing is needed to switch this 
type of inverter, which makes it extremely difficult for reactions, which only cause a 
change of 1 pH unit or less as in Figure 4-1. 
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Figure 4-8 ISFET based chemical inverter 
The PG-ISFET [84] can be used to resolve this issue by incorporating feedback to the 
programmable gate of the ISFET through a cascade of single stage amplifiers as is 
shown in Figure 4-9. As a result the switching of the chemical logic block occurs very 
rapidly even with small changes in pH. When the ISFET is biased with a stable 
reference electrode, typically Ag/AgCl, a potential, h′©  is established between the 
insulator of the device, which contains a pH dependence described by V
chem , and an 
offset due to the presence of trapped charge Vtc  [83]: 
Equation 4-3 
hª©  h© G hR~ G h~ℎ, 
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Figure 4-9 PG-ISFET chemical logic inverter 
 
Equation 4-4 
h~ℎ =  + 2.3 ∙  ∙ R@A 
whereby Ut  is the thermal voltage of the device,  is a grouping of non-chemically 
related potentials and	γ is a number ranging from 0-1, describing the reduction in 
sensitivity from the Nernstian response, typically 59mV/pH. 
Equation 4-5 
hl©  h′© ∙ x2100 % hw© ∙ xw© % hk ∙ x©k % h ∙ x©xn  
The floating gate voltage of the PG-ISFET, VFG , is established by a weighted sum of 
the voltages applied to the reference electrode, through ′VG , and the control gate, 
through VCG , Equation 4-3[85]. Each weight is determined by the capacitance of its 
input normalized by the total capacitance of the floating gate. For ′VG  this occurs 
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through the passivation capacitance, Cpass  and for VCG  through the control gate 
capacitor xw© . Connecting a diode between load and drain of the PG-ISFET and 
cascading the output to another single stage amplifier allows the output of the 
chemical-logic inverter to be described as: 
Equation 4-6 
hw© = Y­1 ∙ Y­3Y­2 ∙ Y­4hl©  
Considering now the case that pH decreases, this causes a decrease in V
chem , which 
causes an increase in VFG , which causes an even larger increase in VCG  because of the 
two gain stages. By employing local feedback of this voltage to the electrical control 
gate of the PG-ISFET, a very rapid transition in V
out  from 0-1 may be achieved for a 
very small change in pH if the device is biased, through the reference electrode, just 
below the switching threshold of the device. A reset switch has been added to ground 
the control gate prior to a reaction so that the inverter may switch. 
The chemical logic inverter in Figure 4-9 was designed and simulated in a typical 
0.35µm process using a Verilog-A model based on the measure results of the 
fabricated PG-ISFET. Figure 4-10 shows the output of the inverter with and without 
feedback when ′VG  is increased ramped from 0-3.3V. What can be seen is that in the 
open loop case due to capacitive division through the passivation the inverter fails to 
switch whereas in the closed loop case it rapidly switches after a voltage of 693.3mV. 
Assuming the PG-ISFET in buffer solution is biased to be below this potential, thus 
any decrease in pH due to a chemical reaction will cause the inverter to switch. Figure 
4-11 shows the results for a decrease in pH from 7.8 V with the reference electrode 
90 | P a g e  
 
biased at 1.47 V. What we can see is that the output switches by changes of 0.1 pH 
and lower satisfying the constraints for the reaction shown in Figure 4-1. 
 
Figure 4-10 Open and closed loop simulated results 
 
Figure 4-11 chemical logic simulation due to a change in pH 
Here we presented a chemical-logic inverter based on the PG-ISFET. By employing 
local feedback the inverter is capable of switching for pH changes as low as 0.1 pH. 
This is useful for identifying chemical reactions such as those produced during base 
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pair incorporation of DNA. This then facilitates the use of standard CMOS 
combinational logic to sequence the genome in a parallel fashion. 
4.5 DNA LOGIC APPLICATIONS 
4.5.1 SINGLE NUCLEOTIDE POLYMORPHISM  
This section presents the application of ISFET-based inverters for reaction threshold 
detectors to convey the chemical reaction level to a logic output once a threshold has 
been reached. Using this, DNA logic functions are derived for nucleotides allowing 
identification of multiple SNPs. This logic is extended to facilitate a combination of 
SNPs, deriving gates, which give a simple Yes/No answer to their presence. A DNA 
logic ‘NOR’ gate is derived for an application where two SNPs need to absent in 
order to determine drug delivery.  
The key aim is to achieve computation out of biological cells and their genetics. In 
this section we propose a novel method of DNA Logic using silicon based transistors 
with chemical interactions to create so called DNA switches that may perform in-vitro 
computation. This particular work will be confined to switching based upon the 
marker for nucleotide insertions, Single Nuclide Polymorphisms, with the application 
being for diagnosis of disease.  
SNPs are receiving considerable interest due to the potential they offer for disease 
diagnosis, screening and personalized drug therapy and medicine. A SNP is defined 
as a mutation of a single base affecting at least 1% of a defined population. Although 
they do not necessarily cause disease, their association with disease and with effects 
on the pharmacokinetics of many drugs provides information for diagnosis and 
pharmacological treatment options for many different diseases. There are currently 
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over 1.8 million identified SNPs. In this section we propose an extension to the 
method of applying ISFET technology to the detection of these SNPs, which could be 
applied to develop a cost-effective disposable device.  
In prior sections, we have shown how the ISFET given a DNA input such as the 
presence or absence of a SNP will cause a change in pH which can be converted to a 
binary output using a simple adaptation of the “NOT” logic gate. Table 4-2 
 
Figure 4-12(A) Measured data from pH response during nucleotide incorporation 
during primer extension when no SNP is present (logic 0) and when SNP is present 
(logic 1) and (b) simulated output from DNA logic inverter circuit 
That principle can be extended to multiple DNA inputs to create other DNA logic 
circuits to perform simple logical operations, which provide a yes/no answer. Often 
the presence or absence of a combination multiple SNPs can give information about 
the risk of genetic predisposition to certain diseases such as heart disease or Type II 
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diabetes [86]. Furthermore, some SNPs are linked to drug metabolism and therefore 
can be used to predict whether a patient should take a high or low dose of certain 
prescription drugs. In the case of warfarin, a blood-thinning agent, a high dose in 
people with certain SNPs could cause excessive bleeding. Two SNPs in particular 
have been found to correspond with lower dose requirements, due to the fact that they 
indicate slower metabolism of the drug. These SNPS are on the “CYP2C9*2” and 
“CYP2C9*3” alleles, and a patient with either or both of these SNPs will require a 
lower dose of warfarin [87]. For illustration, a simplified “truth table” for warfarin 
dose as predicted by CYP2C9 genotype, is shown in Table 4-3. 
CYP2C9*2 CYP2C9*3 Dose 
Absent (0) Absent (0) High (1) 
Absent (0) Present (1) Low (0) 
Present (1) Absent (0) Low (0) 
Present (1) Present (1) Low (0) 
Table 4-3 Truth table of warfarin dose predicted from CYP2C9 genotype 
Table 4-3 corresponds to a “NOR” relationship, which can be implemented using 
ISFET-based DNA Logic. The circuit of the DNA-NOR gate is shown in Fig. 7 where 
the classical MOSFET is replaced with ISFETs at the inputs, with appropriate DNA 
probes and biochemical reagents to detect nucleotide incorporation during primer 
extension [77]. The simulation results are shown in Figure 4-14, where the four 
vertical dash lines divide the simulation into four results corresponding to the truth 
table inputs shown in Table 4-4, where either SNP A or SNP B is present in a DNA 
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sample. This simulation clearly demonstrates that when a single base is detected on 
either ISFET, then the output will be zero. Only if neither ISFET detects a SNP will 
the result be a digital one. 
 
Figure 4-13 DNA Logic “NOR” Gate with ISFET 
 
pH<pHthA 
(SNP A present) 
pH<pHthB 
(SNP B present) 
Vout 
0 0 1 
0 1 0 
1 0 0 
1 1 0 
Table 4-4 Truth table of DNA Logic NOR Gate 
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Figure 4-14 Simulated output response from DNA-NOR circuit for reactions in truth 
Table 4-3 
In this section, we have demonstrated the feasibility of using DNA to switch on and 
off transistors to create a synthetic form of DNA logic. This will be useful in two 
applications, either to create DNA computation as an extension to the work already 
being pioneered within cellular computing or as described in this letter for point-of-
care SNP logic on silicon chip based technologies with the advantages therefore of 
disposability, portability as well as leveraging on the economy of scales of semi-
conductor technologies. 
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4.6 SUMMARY 
Here we have demonstrated the feasibility of DNA logic as a true DNA switch. The 
transistor is controlled by the presence or absence of a DNA target. By combining a 
few DNA logic switches, it is possible to perform genotyping in a POC setting. In the 
next chapter, we are presenting a business model for rapid viral detection using the 
ISFET detection platform. 
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CHAPTER 5  – ISFET PLATFORM HIV NUCLEIC 
ACID TEST     
5.1  INTRODUCTION 
Human immunodeficiency virus (HIV) is known to cause Acquired Immune 
Deficiency Syndrome (AIDS). The spread of the virus is considered by World Health 
Organisation (WHO) pandemic and has caused tens of millions of deaths worldwide 
since the first reported case. UN report in 2009 shows the number of global infection 
is about 30-33 million [88]. The trend of new infection peaked in 1996 as shown in 
Figure 5-1. It is clear that international effort between health regulators, 
pharmaceutical industry, charity organisations and biotechnology companies has paid 
off in reversing HIV spreading.  
The effectiveness of the WHO in dealing with such a pandemic requires close 
collaboration in health policy, disease prevention, HIV diagnosis, therapy and patient 
care and support. One key area in combating the pandemic condition is awareness of 
the infection status for people living with HIV. The initial response of a person 
infected with HIV resembles a flu-like illness in the first four to eight weeks. Typical 
symptoms include fever, headache, diarrhoea, and fatigue. After an initial acute 
phase, the individual usually recovers but may live with HIV without knowing for 5-
10 years before the AIDS illness starts. Without awareness of the infection, there is 
great risk that the disease will spread over the intermediate 10 years. It is therefore 
necessary and critical to implement early detection and constant surveillance of the 
epidemic.  
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Figure 5-1: the statistics of HIV infection between 1990 and 2007 [88]. In recent year, 
2.5- 3 millions are infected every year. 
Awareness of people living with HIV has been one of the obstacles of managing the 
HIV infection. Fewer than 10 percent of people with HIV in Asia and Pacific and less 
than 25% in Sub-Saharan are aware of their sero-status [56, 89]. The undetected 
infection is not specific to developing countries. It is reported that 70 percent of those 
visiting sexually transmitted disease clinics left without known being a HIV carrier in 
developed countries [56, 90, 91]. There has been a new initiative, Provider-Initiated 
HIV Testing and Counselling (PITC), which encourages a more proactive approach in 
HIV testing. With the PICT, the HIV testing is initiated and provided by the primary 
health providers. In one report on immigrants in Belgium, the persistent stigma 
associated with the disease and fear for the outcome has been cited as the reason 
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stopping more uptake of HIV test [92]. In another report, the barrier includes long 
waiting times in getting a test, lack of supporting counselling, and privacy issues [93]. 
The new initiative is to improve testing coverage and therefore to enrol people living 
with HIV to care and supporting system along with existing voluntary counselling and 
testing route.  
 
Figure 5-2: Structure of Human Immunodeficiency Virus. The size of the virus is about 
100 nm in diameter [94].  
To support both initiatives, it is crucial to provide a technology that enables testing 
and improves services. There are rapid HIV tests for diagnosis in field and laboratory-
based detection methods. Each category covers different fields of HIV assays. The 
rapid tests are deployed as the front line transfusion/surveillance/diagnosis, while 
laboratory-based assays are more for confirmation tests and prognosis.  
The rapid tests detect the presence of a human antibody, which is an immune response 
to HIV infection. The human antibody is produced after seroconversion, which is 
about few months after HIV exposure. As the result, there is a window of infection, 
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when the antibody test will fail in detecting the infection. On the other hand, 
laboratory-based methods detect the presence of virus, either protein or genetic, 
materials. Consequently, it is effective in diagnosis for acute HIV infection. One of 
the laboratory-based methods is to monitor the existence of viral genetic material, 
which also has applications in prognosis and care management such as viral load or 
drug resistance.  
The structure of HIV has been studied extensively. The complete particle is also 
known as a virion, comprising a lipid-bilayer jacket and a bullet-shape capsid core as 
illustrated in Figure 5-2. HIV is a retrovirus in which the genetic material is RNA 
instead of DNA. In each virion, there are two identical copies of positive single-
stranded RNA sequence and two copies of reverse transcriptase in the capsid. The 
capsid is made of two thousand copies of viral protein p24. Complementary DNA is 
produced by reverse transcriptase and integrated into the human genome by integrase 
once the virus enters a cell. On the outside, the virus jacket is a mixture viral protein 
gp120 and gp41 with the lipid bilayer originated from the human cell where the virus 
was produced. The number of surface protein, gp120/gp41 is about 70 copies per 
virion. For viral detection in the early course of HIV infection, viral RNA and p24 
could be found in the circulation as early as 1 week after exposure. However the 
circulating p24 will disappear after the acute phase due to the infection cycle of HIV. 
Two species of HIV infect humans: HIV-1 and HIV-2. Both viruses have a similar 
genetic makeup.  The genome is composed of two copies of positive single-stranded 
RNA that codes for the virus's nine genes, enclosed by a conical capsid or viral coat.  
The single-stranded RNA requires enzymes for the development of the virion. One of 
these enzymes, reverse transcriptase (RT), transcribes single-stranded RNA into 
double-stranded DNA. The RNA genome consists of nine genes (gag, pol, env, tat, 
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rev, nef, vif, vpr, vpu, and tev), which in turn encodes 19 proteins. Three of these 
genes, gag, pol, and env, contain information needed to make the structural proteins 
for new virus particles. Genetic sequences within these genes are common to both 
HIV-1 and HIV-2, but not other viruses and so can provide a distinct recognition 
modality.  
It is important to note that the gene sequences of HIV vary between regions and 
individuals due to the high error rate of the genome replication mechanism. The 
variation could be the result of a natural protection for HIV. Change of the genetic 
content result in the mutation in its protein. The chance of evading the host attack 
could be increased by mutations of the envelop proteins which are recognised by 
immune system. Since the structure of HIV is very simple, the odds of a tolerating 
mutation is much larger in HIV than in organisms such as yeast or E. coli. An 
example showing the degree of variations in three geographical populations is shown 
in Figure 5-3. It is therefore very important that the design of any HIV diagnostic kit 
takes into account the dynamic variation of the genes. It is also known that the 
dominant HIV strain in an individual living with HIV could change depending on the 
treatment regime and the discipline of exercising the regime [95]. It is usual that there 
are more than one strains of HIV co-infected a patient. The mutations or gene 
variations may or may not be associated with drug resistance. The HIV medications 
have to take these issues into account to deliver specific treatments. Therefore the 
effectiveness of the therapy is correlated with the surveillance and early diagnosis of 
the gene variations.  
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Figure 5-3: Phylogenetic tree of 197 HIV-1 samples from Kinshasa and from Bwamanda 
and Mbuyi-Mayi in Democratic Republic of Congo. The 0.1 bars at the bottom of the 
graph represent 10% variation [96].  
Following infection with HIV, the virus binds to and enters a class of white cells 
known as T-lymphocytes. Only a subset of T-lymphocytes carrying cluster of 
differentiation 4 (CD4) is infected as the route of entry. The invasion of the HIV virus 
particle is initiated by the binding of CD4 receptor to the gp120 on the envelope of 
HIV particle, which initiates endocytosis processes [97].   
The HV replication is illustrated in Figure 5-4. After a cell is infected, HIV multiplies 
within the CD4+ lymphocytes and is then released by killing the cell and releasing 
virus particles that then infect further CD4+ T-cells.  
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Figure 5-4: Primary HIV infection and replication. HIV particle associates with human 
lymphocyte via interaction between gp120, CD4, and CCR5 [98]. 
In a few weeks after viral exposure, the HIV replication process reaches a maximum 
as well the number of circulating virion. Billions of virus particles are produced each 
day in the acute phase and the individual is highly infectious at the stage.  During this 
acute phase of the infection there are no overt symptoms although the body is 
producing antibodies against the virus, specifically against the gp120 protein. Also 
during the acute phase there is an increase in virus particles and a fall in T-cell 
numbers which we can see in the viral load and cell count in Figure 5-5.  
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Figure 5-5: Viral load and immunological response of HIV infection. 
Sometime in the 3-6 months following infection the individual ‘seroconverts’, the 
level of antibody reaches a plateau, virus numbers fall and CD4+ cell numbers recover. 
This asymptomatic state can last for years and it is usually during this period that 
individuals are diagnosed as being HIV positive.   
It is not surprising that people living with HIV do not understand the viral conditions 
until the start of the AIDS illness due to the very long asymptomatic period. In more 
developed countries, late diagnosis contributes to a substantial proportion of newly 
infected HIV individuals [99, 100]. The late diagnosis has several implications in HIV 
management and care support. The choice of medication is limited in the AIDS stage 
and the health condition of the individual generally is too poor to support the therapy. 
Strategies to improve the early diagnosis are proposed to include routine HIV test in 
primary care condition such as the PITC scheme and providing HIV tests in non-
medical environments where adequate counselling is available [101].  
Studies show that early detection of the virus could radically prevent the spread of the 
disease. The majority of the peoples, who learned that thy are HIV positive, tends to 
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modify their behaviour to reduce the risk of HIV transmission [102, 103]. In addition, 
early detection of the virus also reduces morbidity and mortality and improves quality 
of life 
5.2 HIV TESTING OVERVIEW 
The testing can be classified as diagnosis and prognosis, in which diagnosis provides 
result for people newly living with HIV and prognosis offers the therapeutically 
effectiveness and medical support.  
 HIV diagnosis generally tests for the presence of antigen or antibody specific to HIV-
1 and HIV-2. A reactive result indicates the presence or history of HIV infection. The 
standard WHO/UNAID protocol on HIV assays includes three strategies in calling the 
assay result as shown in Table 5-1.  For screening of donated blood or organs for 
HIV, a one-step test is carried out. ELISA is usually used to in the strategy for its 
ability to process large quantities of samples with low cost. Reactive response or 
intermediate results will result the donated sample being discarded. When individuals 
are in clinical counselling for HIV, the diagnosis involves loops of testing using 
different methods and mechanisms depending on the prevalence of the case. In low 
prevalence situations such as early diagnosis when there is no symptom of illness, a 
supplement test is needed to confirm a positive reading. One of the confirmatory tests 
is Western Blot (WB), where the antibody specific to HIV proteins are being verified. 
WB requires more skilled intervention and is not designed for the first test.  
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Table 5-1: HIV testing strategies and test objective [104].  
Another class of first-line HIV test is the rapid test, which produces result in less than 
30 minutes. The rapid test can be performed in the field using whole blood, serum, 
urine, or even saliva samples. The rapid test could be used as a screening assay as a 
well as diagnostic assay.  
When the objective is medical support for people living with HIV, viral load and drug 
resistance are the focus. The viral load indicates the effectiveness of the medication. 
A viral load lower than 50 copies per ml of blood is considered as undetectable. 
Increaseing viral load is a rebound and sign of the failed therapy. Nucleic acid test is 
the standard methods in viral load assay. The test quantifies the amount of the viral 
RNA or pro-DNA using nucleic acid amplification technologies such as PCR. The 
type of assay is extremely sensitive and a much shorter window period compared with 
an antibody/antigen assay. However, specialised facility and training is required to 
ensure the test quality, which associates with much higher cost. The turn-around time 
is generally several hours before the result is available [105]. 
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Figure 5-6: ELISA work flow example. In this example, the target antigen could be 
recombinant HIV fragments. The sample is applied to the immobilised antigen. If there 
is HIV-specific antibody, it will bind to the antigen. The detection of the antibody by 
immunoglobulin binder produces colour or light [75]. The graph is an illustration of a 
general work flow.  
5.2.1 ANTIBODY AND ANTIGEN TESTS 
These type of tests covers a broad range of products and assays. HIV antibody tests 
are highly sensitive and have advantages of being inexpensive and accurate. This 
makes it the most apposite test for routine viral detection. One of the first HIV test to 
be widely used is the enzyme-linked immunosorbent antibody test (ELISA, Figure 
5-6). The type of assay could be automated in microliter plate format, which allows a 
really large volume of samples. When used in diagnosis, ELISA positive can be 
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inconclusive. Risk history of the individual, and clinical judgment on the visit should 
be included in the assessment. A second independent test is required as a confirmation 
test.  
The emerging rapid tests circumvent the long turn-around time and provide 
alternatives to regions with limited resources and low sample numbers. The principle 
of detection of the rapid testing kit is the same as the ELISA. The rapid kit has the 
antigen and reagents packaged in a compact and machine free format. Typically 
recombinant peptides resembling the HIV proteins are immobilised on a membrane. 
In the presence of antibodies specific to HIV, the antibodies bind to the peptides on 
the membrane. These antibodies are only produced after seroconversion by the human 
body as the response to HIV invasion. The detection of the antibody-peptide complex 
is achieved by labelled immunoglobulin binder, such as protein, a from of bacteria. 
The immunoglobulin binder could be labelled with gold nano particles. When the 
binders are concentrated at the line/dot of the HIV antibody, a visible line or dot will 
appear. The detection cascade is sensitive and simple. Many of the tests have been 
granted CLIA waiver status in using whole blood samples (Table 5-2).  
However, a clear disadvantage of antibody tests is the false negative result during the 
acute phase of infection. This is due to the gradual development of detectable HIV 
antibodies. The vast majority of people take approximately 30 days after infection for 
their antibodies to be noticeable.   
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Brand Time  Viral type Sample type Format 
OraQuick 20  HIV 1/ HIV 2 Blood, plasma or oral fluid 
 
Uni-Gold 10 HIV 1 Blood, serum, or plasma 
 
Clearview  15  HIV 1/ HIV 2 Blood, serum, or plasma samples 
 
Reveal HIV 20  Whole blood, serum, or plasma. 
 
Table 5-2: The short list of third generation HIV rapid tests.  
5.2.2 NUCLEIC ACID TESTS 
There is clinical correlation between the concentration of circulation virus and 
progress and risk of AIDS. When newly HIV positive, the supporting system will 
decide the therapy regime based on the individual living history, any medical 
complications, and the viral load in blood.  
For people who have lived with HIV, a key indicator of anti-retroviral treatment 
(ART) failure is an increase in viral load. Currently the turnaround time for such tests 
is usually one week, and in the event that a patient on ART has an increased viral 
load, it is necessary for the patient to re-attend clinic, commonly four weeks from the 
time of the first appointment, and during this period it is likely that drug resistance 
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will have continued to develop, thus limiting the available options for changes in the 
drug regimen. The development of a lab-free HIV viral load test would serve to avoid 
such problems and reduce laboratory costs in a UK setting, as well as being a priority 
in global health to determine ART failure (instead of CD4 cell count/clinical 
symptom development) and to diagnose mother-to-child transmission (instead of 
antibodies which limits tests to children 18 months of age). The work proposed would 
validate the detection and quantification of both viral HIV RNA and proviral DNA, 
paving the way to develop diagnostics for other viruses including hepatitis B and C. 
 
 
Figure 5-7: The fluorescence signal during a PCR. Threshold cycle number is usually 
used as the parameter in quantitating the amount of starting material [106].  
Nucleic acid test (NAT) currently is the only established method for determine the 
viral concentration in the circulation. In the test, sample RNA or DNA, is amplified 
using polymerase mediated synthesis. The ratio of the product to the sample would 
reach 108-9 at the end of the reaction. The speed of amplified nucleic acid 
accumulation is proportional to the amount of input sample. Quantification is done by 
comparing the accumulation against a known control. The amplification is hard to 
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match by ELISA while obtaining the specificity. Over the last twenty year, PCR has 
become the standard to quantify the small amount of nucleic acid which is otherwise 
undetectable [106-109]. The quantitative detection happens at the same time as the 
amplification. As the result, the method is also called real-time PCR. There are many 
techniques in obtaining the real-time quantification, which invariably require 
fluorescent intervention. One of the examples of the quantitative PCR is shown in 
Figure 5-7, where the technology is Sybr Green PCR.  
The cost of a NAT assay is, however, considerably much more expensive compared 
with ELISA assays. If large sample number are to be processed using NAT, current 
products on the market would require substantial advanced instrumentation to be 
setup and automated. Although NAT is not being used as a primary assay for 
diagnosis, it could shorten the window period between infection and detectability of 
the disease. In order to enable NAT in a point of care environment, it will need new 
technology to circumvent the assay cost and machine complexity.  
When using biological sample for NAT, the current protocol requires viral RNA is to 
be purified to high grade before amplification. It removes sample difference and 
inhibitors which affect polymerase. The following step is to convert RNA into cDNA 
by reverse transcriptase (RT) before being amplified by a second enzyme cassette.  
PCR is the technology behind the Tagman assay [76], for example. Sets of short 
oligonucleotides specific to viral genome bind to the viral cDNA. The amplification is 
then followed using the hybridised oligonucleotides. Detection is by the hydrolysis of 
a labelled reporting oligonucleotide, which is specific to the amplified product. The 
release of the labelling probe is detected as fluorescence increases.  
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Amplification could also be achieved using T7 RNA polymerase/reverse transcriptase 
cassette in Gen-Prob products. After amplification, the resulting nucleic acid products 
are hybridized to specific oligonucleotides bound to the vessel wall, and are then 
made visible with a probe bound to an enzyme. The amount of virus in the sample can 
be quantified with sufficient accuracy to detect three-fold changes. 
 
Figure 5-8: Branched DNA (bDNA) detection. The target nucleic acid is captured by 
capture probe, which is immobilised on the surface. The enzyme (Alkaline phosphatase) 
is conjugated to the bDNA [110]. 
There is another class of NAT which does not use polymerase to amplify the nucleic 
acid but use enzyme to amplify the signal. Branched DNA technology from Chiron 
uses densely packed enzyme on a recognition branched nucleic acid which associates 
to the target complex through hybridisation [110]. The target complex comprises 
capture/amplifier/preamplifier oligonucleotides as shown in Figure 5-8. Capture 
oligonucleotides are added to bind and immobilise the extracted RNA to the wall of 
the vessel. Amplifier and preamplifier oligonucleotides are added to bind at several 
locations with the RNA. Finally bDNA with enzyme conjugates bind to several 
locations to those oligonucleotides. The densely packed enzyme action causes a 
colour reaction, which allows quantification of the viral RNA. Monitoring the effects 
of antiretroviral therapy by serial measurements of plasma HIV-1 RNA with this test 
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has been validated for patients with viral loads greater than 25,000 copies per 
millilitre. 
The NAT assay is effective in early diagnosis and essential in prognosis. There is a 
clear advantage for HIV detection and quick viral load results. However the 
performance of these methods mentioned, are not designed for a POC environment. 
With the advance of PCR technologies, improvement on polymerase performance, 
and integration with microfluidic structures, a new generation of NAT is coming to 
address the need. The first wave of the technology advance is the integration of the 
miniaturisation and traditional fluorescent PCR or hybridisation technologies. FDA 
approved assays and product such as Osmetech (eSensor® XT-8 Warfarin sensitivity) 
and Cepheid (XpertTM MRSA) are starting to test the acceptance in primary care 
environment. Despite the use of microfluidic structure and microchip, they require a 
large instrumental setup combining amplification and detection. As the result, these 
methods are classified as chip-in-a-lab devices. 
5.3 ISFET NAT PLATFORM  
We propose the ISFET NAT platform could provide an alternative to the current NAT 
methods based on the following: 
1. Disposable sensor and analyser 
2. The integration of detection of nucleic acid and amplification with CMOS is a 
true lab-in-a-chip technology.  
3. It is versatile to form the platform into a high-density automatic unit or rapid 
result in a resource restricted environment.    
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Our objectives are to implement HIV detection in a point of care setting and to bring 
personalized medicine to the bedside in the management of infected patients with 
HIV. In addition to its timeliness in developing POC testing which will be of 
immediate benefit to patients, the section of this thesis will serve as a proof of 
principle for POC detection and quantification of other infectious organisms. The 
work will also be important in the development of a lab-free rapid NAT assay needed 
in the developing world and for HIV and other diseases.  
 
Figure 5-9: The goals and project of HIV-1 diagnosis. The projected project uses ISFET 
technology and one-step RT-PCR for viral amplification.  
This work contributes to the proof-of-concept step which amplifies and detects the 
HIV virus in a simplified condition. The enabled technology platform will be 
incrementally developed to exploit its potential as a POC detection system for HIV-1 
virus load testing and streamline the sample preparation (Figure 5-9).  
The concept structure of the ISFET NAT platform is shown in Figure 5-10. It has 
been verified that the ISFET reads pH change on a nucleic acid chain extension that 
generates protons. The presence of a matching target sequence correlates with H+ 
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release as shown in the graph. The logic is established between the nucleic acid target 
and the ISFET readout. The method is highly scalable because 
1. No camera or optical detector needed  
2. Mass manufacturability powered by use of the standard CMOS process  
 
Figure 5-10: Device structure of POC ISFET device. Multiple sensors are integrated 
with corresponding fluidic structures. Detection of reaction is carried out in each 
discrete electrode.  
5.4 LABEL-FREE HIV-1 DETECTION BY ISFET 
A non-infectious strain of HIV-1 virus, 8E5 from SeraCare was used as the model 
sample. The virus is purified from cell culture and mixed with screened human serum 
with known concentration, 20,000 copies/mL. The virus has same sequence and 
structure as standard HIV-strain, HXB2[111], apart from one mutation at 3241 
position which causes a frame shift to the polymerase [112, 113].  
The development of the test has accomplished ISFET detection using a one step PCR  
divided into three stages,  
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1. Sample preparation 
2. Validation of design and rt-PCR 
3. pH-PCR of HIV in one step 
The sequence of the primers used in the rt-PCR has been tested and optimised (Table 
5-1). It is found that the extra primer (SID4) for reverse transcription step increases 
the yield significantly. The PCR primers (SID5/SID6) amplified the ssDNA initiated 
by SID4.  
Name Sequence 5’ → 3’ 
SID4 CTGTAATAAACCCGAAAATTTTGAA 
SID5 ACGGTTAGGGCCGCCTGTT 
SID6 TTCCCCTGCACTGTACCCCC 
Table 5-3: The sequence of oligonucleotides in HIV RT and PCR 
Typical rt-PCR started with two steps PCR. In the first step, the reverse transcriptase 
(SuperScript III from Invitrogen) is mixed with SID4 and HIV RNA in proprietary 
buffer. The reaction is allowed to occur for 30 minutes, which produces cDNA. The 
reaction mixture is then heat-inactivated at 95⁰C for 5 minutes.  
 
Figure 5-11: Alignment of SID4/5/6 to the HXB2 sequence. 
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The cDNA from RT is then amplified using the PCR technique. Optimisation was 
done by varying the annealing temperature and concentration of primers. The 
amplification produced a greater pH decrease compared with a control reaction, as 
shown in Figure 5-12. In the control, one of the PCR primers was missing and there 
was no reaction happening in the control. A successful PCR requires both forward 
and reverse primers. The extension reaction only multiplied the template linearly by 
cycle number rather than exponential in a typical PCR. The missing primer was 
replaced by an equal amount of counter primer to compensate the buffer capacity 
variation. 
The data shown in Figure 5-12 is the pH dependence on the PCR progress using 
cDNA. Each point was triplicated. The pH value at 5 cycles was used as the starting 
point, where the samples were cycled without substantial amplification. As the PCR 
progress, more amplicons are produce. As dNTPs converted to pyrophosphate in the 
PCR catalysed by polymerase, the pH decreased from 7.6 to 7.1. However, there is 
also a pH drop in the control between 5 and 35 cycles. This was likely caused by non-
specific hydrolysis of dNTP, which was caused by thermal cycling.  
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Figure 5-12: Amplification dependent pH change. Value of pH was measured at 5, 35, 
and 45 cycles of PCR using cDNA. The cDNA was prepared in a separate step by 
SuperScript III. 
Integration of reverse transcription and PCR was not straightforward. Different 
enzymes are used in each reaction, in which the RT enzyme interferes with 
thermophile polymerase in PCR. Research work has been carried out trying DNA 
polymerases from various suppliers (Table 5-4). It is found that the combination of 
Invitrogen and Fermentas provided most consistent results. Crucial optimisation is 
done on mixing the right ratio of the RT enzyme and thermophile polymerase. A 
single reaction mixture is achieved to combined RT and PCR in a sealed chamber.  
The graph in Figure 5-13 shows a much bigger difference between the starting pH 
(cycle 5) and end pH (cycle 45) in the presence of HIV.  The apparently lower starting 
pH in the control is the result of variation between assays. The reading of the signal is 
depending on the pH difference between two or more cycle numbers.  
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Company Product 
Invitrogen AmpliGold 
Fermentas TrueStart 
Promega GoTaq 
Clontech Titanium Taq 
KBiosciences Klear Taq 
Table 5-4 Enzyme vendors and products used in the assays 
 
Figure 5-13: pH detection of HIV using one-step RT-PCR method 
5.5 DNA LOGIC IN ISFET PLATFORM NAT HIV TESTS 
Given the validated result in HIV detection using the ISFET, we designed an 
integrated DNA logic chip that combines the pH signal and decision making using 
transistor. For diagnosis, a device should help the user to reach a decision, such as the 
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type of drug or therapy care. Direct and concise instruction from the device is 
generally favoured without presenting raw signal or data such as the graph in Figure 
5-13. Based on the concept, the DNA logic chip is to provide a logic operation on the 
ISFET signals from each target chamber shown in Figure 5-10. The result of the 
operation can offer simple binary result, Yes or No.  It is essential to contain both 
negative and positive controls in any molecular diagnosis device. More control 
reactions are generally required to provide the noise level of non-ideal conditions. In 
HIV tests, the negative control is a reaction using buffer in the place of a template 
nucleic acid, which is called NTC control.. A synthetic target, RNA, is used as a 
positive control. A logic table in Table 5-5 reduces the assay result into a different 
infectious status or failed test. The confirmed positive requires both positive control 
and HIV sample being responsive while the buffer remains negative. A design of the 
trial chip is shown in Figure 5-15.  Three reaction chambers and ISFETs are located at 
the corners of the square.  
 
Table 5-5 Logic Truth Table: Buffer = Negative control RNA = Positive Control 
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Figure 5-14: Three ISFET inverter pair circuit design of the logic table of three ISFET 
chambers 
 
Figure 5-15: Floor plan of HIV logic chip, 1.5mm spacing between inverters 
Logic gate design can also be applied to a sequence selectivity test. In the previous 
session, the principle of HIV detection using pH is shown. There is only one target 
sequence, which is part of the pol gene. However, it is normal to test multiple sites of 
HIV sequences to increase the selectivity. Conserved regions in the viral genome such 
as pol or gag are the frequent targets. Another conserved region is vif gene, which is 
used in the Roche detection kit along with gag.  Here we present the logic gate design 
that accommodates two sequences such as gag and vif for the detection of HIV-1. The 
accuracy of testing is vitally important in order to access treatment, and knowledge of 
one’s positive status can lead to behaviours to protect other people from infection.  
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gag vif gag ⋅ vif  
0 0 0 
1 0 0 
0 1 0 
1 1 1 
Table 5-6: Truth table of genes, gag and vif 
By having an “AND” gate, output 1 will only be given with both genes gag and vif 
are present in either blood or saliva samples. As a result, “AND” gate make feasible 
for more sensitive and more robust HIV-1 nucleic acid testing. This is an important 
step for such detection at home or at any POC setting without skilled personal and 
laboratory.  
5.6 SUMMARY 
HIV diagnosis is currently dominated by antibody-based assay. The kits described in 
the chapter provide detection with the risk of missing the early infection. The health 
authorities have managed HIV diagnostic policies based on the available detection 
technologies. The DNA logic and labelling free detection could improve the HIV 
management by increasing the sensitivity over the window period. We have 
demonstrated the proof-of-concept of the detection using ISFET. The detection and 
discrimination is directly correlated with the degree of amplification. By combining 
the HIV assay and DNA logic, it is possible to produce a single device that can 
indicate the early infection of HIV.  
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CHAPTER 6  – RAPID HIV TESTING: BUSINESS 
MODEL OVERVIEW 
6.1 INTRODUCTION 
Human Immunodeficiency Virus (HIV) is a compelling health issue that is currently 
plaguing the globe. This anxiety stems from the AIDS pandemic. First recognized in 
1981, AIDS precipitated the death of more than 25 million people [114]. Present day, 
it is considered one of the most detrimental diseases recorded in history. 
In spite of the constant advancement of antiretroviral treatments, AIDS is consistently 
still one of the most detrimental epidemics in the world. According to studies 
compiled by the Joint United Nations Programme on HIV/AIDS (UNAIDS), globally 
there are approximately 33.4 million people currently living with the disease. In 2010, 
it was surveyed that 2.7 million new cases of AIDS arise every year [115].  
One of the key factors that contributed directly to this catastrophe was the insufficient 
amount of funds allotted for preventative measures and lack of access to antiretroviral 
treatment.  In Kenya, antiretroviral therapy was offered to approximately 190,000 
adults, but there is an estimated of 1.4 million existing HIV-infected patients. Only 
12% of infected adults were receiving the treatment. In other words, more than half of 
infected patients are still not receiving antiretroviral therapy [116]. 
There has been a lot of debate regarding the amount of funds allotted for HIV/AIDS 
in the healthcare sector.  This has been such a controversial matter because it has 
become an enormous burden on government budgets and resources. In 2006, $8.9 
billion was spent globally on HIV/AIDS activities. The spending only achieved 60 
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percent of the global need. Although the spending in 2008 was increased to $13.7 
billion, the fund was still 48 percent short of the actual global demand. Furthermore, 
UNAIDS estimated that the fund required for HIV/AIDS activities in 2010 will reach 
$25.1 billion and forecasted that by 2015 the annual resource need will surpass $54 
billion [117] Figure 6-1. 
 
Figure 6-1 Global Spending on HIV/AIDS Activities [118] 
Besides causing extreme grief and pain to loved ones, HIV and AIDS cause long-term 
permanent damages on the global economy and the obstruction of human capital 
growth. This is due to the impacts resulting from the increase in the proportion of 
young adults affected with HIV/AIDS. This pernicious disease has gravely crippled 
the taxable population and also reduced the amount of funding that was provided for 
public expenditures including education and health services [118].  
Although governments and organizations have taken great care to implement 
preventative actions to impede the growing number of HIV/AIDS patients, the 
amount of victims that suffered from the contamination rose greatly regardless of 
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their immense efforts.  Thus, vigorously expanding access to HIV counselling and 
testing shows the most potential to diminish the HIV/AIDS population. Implementing 
early HIV detection is without doubt a gateway into HIV prevention, treatment and 
care.  
6.1.1 EARLY HIV DETECTION 
Early HIV infection often causes no symptoms, making early detection extremely 
difficult. Present day, HIV testing programs rely heavily on HIV antibody tests 
because they are cheap and effective. However, HIV antibodies generally do not 
reach noticeable levels in blood for one to three months after infection. It may take 
the antibodies as long as six months to be produced in quantities large enough to show 
up in standard antibody tests [119]. 
In a 2006 UK report [120], it claimed that one quarter of an infected population visit 
and leaves the clinic not knowing they are HIV positive. This presents a particularly 
high risk, as subjects with acute HIV infection are most contagious because of high 
virus loads in their system. The reason causing false negative results is due to the 
intrinsic defect of any antibody-based tests within the window period before 
seroconversion. Thus, false negative results within this highly contagious period can 
pose a serious challenge in controlling such an epidemic. Hence, to determine 
whether a person has been recently infected, screening blood for the presence of HIV 
genes is consider one of the most effective method to avoid false negatives results. 
Direct screening of HIV genes is extremely critical in preventing transmission of HIV 
from recently infected individuals.   
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6.1.2 NUCLEIC ACID TESTING MARKET 
Nucleic acid tests (NAT) is one of the fastest growing segment in the molecular 
diagnostics market. It is widely being used for improving IVD tests, tailoring 
personalized medicines, and discovering novel biomarkers. The growth of the NAT 
market is mainly driven by various applications such as viral load applications in 
HIV/hepatitis, detection of pathogens, and Cytomegalovirus (CMV) diagnostics. As a 
result, this thriving market is projected to reach 5.6 billion USD by 2015 [121].  
NAT outperformed the traditional chemical reaction techniques in terms of sensitivity 
and sample to readout time, making NAT the most advanced diagnostic test for 
examining pathogens of interest and various genetic disorders. In addition, NAT is 
currently the only established method for determining the viral concentration in the 
circulation. This is particularly essential when it comes to therapeutic effectiveness 
and medical support. Although, in recent years, the advancement of NAT 
technologies has made the NAT more accessible, the adoption of NAT in the clinical 
laboratory field has been rather slow due to high cost and lacking in skilled lab 
personal [121]. 
Major players in NAT market include:  
 Abbott Laboratories Inc. is a global company leading in the IVD business, 
specializing in immunoassays and blood screening. Various applications of 
medical tests and diagnostic instrument systems have been developed by Abbott. 
Abbott offers hospitals, laboratories, blood banks, and physician offices to 
diagnose and monitor diseases such as HIV, hepatitis, cancer, heart failure and 
metabolic disorders. Abbott also manufactures POC diagnostic products for 
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blood analysis and cardiac assays to provide immediate and precise diagnostics 
information [122]. 
 Applied Biosystems Inc. is a company that focuses on pharmaceutical, 
biotechnology and standardized testing researches. The company has an installed 
base of nearly 180,000 instrument systems in 100 countries. Applied Biosystems 
Inc. products have been widely used by pharmaceutical and biotechnology 
companies for enhancing discovering and developing new drugs [123, 124]. 
 Becton, Dickinson and Company, founded in 1897, is a medical technology 
company that manufactures, and sells medical systems and instruments. Its 
diagnostics department provides one-stop solution integration systems from safe 
collection and transport of diagnostics specimens to instrument systems and 
reagents for infectious diseases detection, healthcare-associated infections (HAI), 
and cancers. Its product lines include of safety-engineered blood collection 
products and systems, automated blood culturing systems, molecular testing 
systems for sexually transmitted diseases and microorganism identification and 
drug susceptibility systems [125]. 
 Myriad Genetic Laboratories, Inc. is most famous for its predictive medical 
products: [126] 
I. BRACAnalysis: evaluates risk for hereditary breast and ovarian cancer 
II. COLARIS: evaluates risk for hereditary colorectal and uterine cancer 
III. COLARISAP: evaluates risk for adenomatous polyposis colon cancer syndromes 
IV. MELARIS: evaluates risk for hereditary melanoma 
These predictive medical products patented by Myriad Genetic account over 
40% of its revenue. 
Myriad also offers the following personalized medicine tests: [126] 
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I. TheraGuide: predicts toxicity to 5-FU-based chemotherapy 
II. OnDose: measures a patient’s exposure to 5-FU chemotherapy  
III. PREZEON: assesses the status of the PTEN gene 
IV. PROLARIS: assesses the aggressiveness of prostate cancer  
Myriad is one of the leading companies to make its profit through genome 
discoveries. 
 Novartis AG is a Switzerland-based holding practicing research, development, 
manufacture and marketing of healthcare products. Novartis provides healthcare 
solutions include medicines, preventive vaccines, diagnostic tools, generic 
pharmaceuticals, and consumer health products. Operating in over 140 countries, 
its businesses are divided into four operating departments: [127] 
 Pharmaceuticals: discovery and developing new medicines  
 Vaccines and Diagnostics: developing human vaccines and blood-testing 
diagnostics 
 Sandoz: generic pharmaceuticals development  
 Consumer Health: manufactures and develops over-the-counter (OTC) 
medicines, animal health medicines, and contact lenses products.  
 Roche’s Diagnostics Division, in 2009 had a 20% share of the global IVD 
market, valued at an estimated 40 billion US dollars in annual sales. It is one of 
the top suppliers in the IVDs market. In addition, Roche’s research products are 
widely used in hospitals and research labs for pathogens researches and 
discovery of new treatments [128]. 
 Siemens Healthcare Diagnostics, Inc. manufactures and provides clinical 
diagnostics and therapeutic systems. It has a wide range of product lines such as 
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integrated chemistry, immunoassay, routine chemistry, diabetes, urinalysis, 
blood gas monitoring, early detection, diagnosis, therapy, and care [129]. 
6.1.3 CHAPTER OBJECTIVES 
The proposition of this chapter is to propose a business model using the ISFET 
chemical sensing technology as a platform to implement rapid HIV nucleic acid tests. 
In this Chapter, we started with a thorough analysis of the HIV testing market and a 
brief overview of current HIV testing products and manufacturers. Next we depicted a 
business opportunity using ISFET chemical sensing platform as a low cost, rapid, and 
robust HIV point of care detection device by constructing a business model with 
strategic comparative analyses and a revenue model. 
6.2 HIV TESTS: MARKET OVERVIEW 
6.2.1 INTRODUCTION 
As we have mentioned in Chapter 4, HIV tests can be classified as diagnosis and 
prognosis, in which diagnosis provides result for people newly living with HIV and 
prognosis offers the therapeutically effectiveness and medical support.  
There are three main objectives for HIV diagnosis tests:[130] 
I. Screening donated blood to reduce transmission of the virus through 
transfusions 
II. Surveillance of HIV prevalence 
III. Diagnosis of infection in individuals 
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The accuracy of HIV tests is measured by their sensitivity and selectivity. These 
operational parameters are determined by clinical condition of the patient, operator, 
environment, package design, and principle chemistry.  
I. Definition of sensitivity: null response in false negative. e.g. 2 false negative in 
100 known positive samples, sensitivity is 98% 
II. Definition of selectivity: null result of false positive. e.g. If there are 4 false 
positive in 100 known non infected samples, selectivity is 96% 
When the objective is to minimize false negative results, high sensitivity tests should 
be used. Otherwise if the objective is to minimize false-positives results, tests with 
high selectivity should be used. Present day, the sensitivity and selectivity 
requirement for a HIV test are 99% and 98% respectively. Due to cost-effectiveness 
and characteristics of various HIV tests, in practice, different types of tests are often 
used in combination to utilize limited resources [130]. 
Viral load and drug resistance are the focus when the objective is medical support for 
HIV patients. The viral load is a significant effectiveness indication of the HIV 
medication. Normally, viral load lower than 50 copies per ml of blood is considered 
as undetectable and an increase of the viral load during antiretroviral treatments is 
consider a rebound and sign of the failed therapy [131]. 
Nucleic acid test (NAT) is the standard methods in viral load assay. NAT is extremely 
sensitive and has a much shorter window period comparing with antibody/antigen 
assay. However, specialized facility and training is required to ensure the test quality, 
which associates with higher cost. The turn-around time is generally several hours to 
days before the test results are available [132]. 
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The advancement of antiretroviral treatments has significantly improved therapies 
offered to HIV/AIDS infected individuals, which made HIV emerges as a persistent 
condition that needs efficient disease management rather than a life threatening 
disease. This not only prolong the lives of infected patients but also increased and 
encouraged people to have HIV tests when they find themselves exposed to HIV in a 
high risk situation. Thus, players in this sector have been motivated to develop more 
efficient, more robust, and more sensitive HIV testing products.  
6.2.2 MARKET OVERVIEW 
According to Global Industry Analysts, Inc, HIV screening tests market is projected 
to yield US$1.3 billion revenues by the end of 2010 and is projected to exceed $3.9 
Billion by the year 2015. Although Africa, China, and India account for over 90% of 
world HIV population, according to the 2008 report, 60% of the worldwide HIV 
testing market is in United States and Europe. However, Asian countries such as 
China, India, and Southeast Asia are projected to encounter the fastest growth in 
demand for HIV tests in the next decade due to their economic growth and health 
education. This phenomenon is particular especially in China, booming market has 
pushed Chinese government to reform its health-care policies and increase 
government spending in the medical sector of its annual fiscal expenditure. These 
markets are very promising and offer enormous potential for manufactures with 
HIV/AIDS testing products [133]. 
By 2015, HIV viral load monitoring test market is projected to reach US$1.7 billion 
due to the advancement of antiretroviral treatments. However only countries such as 
US and Europe, accounting for roughly 75% of the monitoring test market, can afford 
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and access such treatments. In addition, in US alone, HIV/AIDS confirmatory test 
market is projected to reach US$32 million by 2015 [133]. 
The rapid test kits market is one of the fastest growing HIV testing markets. It is due 
to the nearly instant results as they claim to offer. Comparing with enzyme-linked 
immunosorbent assay (ELISA) testing kits, rapid test kits are easier to use with faster 
results. 
6.2.3 CURRENT KEY PLAYERS IN HIV TESTING MARKET 
Key players in HIV/AIDS testing market with significant presence (Table 6-1):  
 Abbott Laboratories produces HIV medicine Kaletra and Aluvia. According to 
WHO, Kaletra/Aluvia is the most widely registered HIV medicine in the world, 
approved in 170 countries [122, 124]. 
 Adaltis Inc. is a company whose primary product for HIV tests is the Nexgen 
Four/Personal Lab instruments. 
 Siemens Healthcare Diagnostics is one of the most advance HIV testing product 
manufactures. Its ADVIA Centaur HIV Ag/Ab Combo assay claims to aid in the 
early detection and diagnosis of HIV infection by simultaneously detecting the 
presence of both the p24 antigen and the HIV antibodies. The ability to detect 
both the antigen and the antibodies at the same time can increase the likelihood 
of early detection and treatment for HIV patients [129]. 
 Bio Mérieux offers two test ranges, QUICKVUE and VIKIA. These rapid 
tests are designed to resolve the difficulties implementing diagnostic tests at a 
point-of-care (POA) setting. QUICKVUE and VIKIA tests cover a wide range of 
infectious diseases such as HIV, Hepatitis B, Influenza, RSV, Viral 
Gastroenteritis, and Chlamydia. 
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 Calypte Biomedical Corporation develops innovative in-vitro diagnostic testing 
solutions for HIV. The tests are known to be reliable and rapid non-invasive HIV 
diagnostic tests. 
 Innogenetics NV. develops and markets diagnostic products in the area of 
infectious diseases include screening and confirmation tests for HIV, HCV, 
HTLV, and syphilis; genotyping tests for hepatitis B virus (HBV), human 
papillomavirus, and mycobacterium sp; and drug-resistance tests for TB and 
HBV. 
 OraSure Technologies Inc. develops, manufactures, markets, and sells oral fluid 
diagnostic products. OraSure’s HIV testing products include OraQuick 
ADVANCE HIV-1/2, a point-of-care test for antibodies to the HIV-1 and HIV-2 
and OraSure, an oral fluid collection device for the detection of antibodies to 
HIV-1. Further, the company also sells immunoassay tests and reagents for 
western blot HIV-1 confirmatory test. 
 Roche Diagnostics quantitative tests for HIV-1 provide health information to be 
used by physicians, helping them to determine viral load and monitor their 
patients' disease progression and response to therapy [128]. 
 COBAS AmpliPrep and COBAS TaqMan systems are the first fully automated 
real-time, continuous load IVD platform for infectious diseases detection such as 
HIV-1. It has features of sample-in and result-out capability. It is designed to 
increase laboratory efficiency and productivity with automated sample 
preparation, amplification and quantitation of RNA/DNA.  
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 Product name Sample source Time 
HIV 
GENOTYPING 
Bayer : TRUGENE® HIV-1 
genotyping assay 
Plasma RNA amplified by RT-PCR 
Detection by sequencing electrophoresis 
Many hrs 
Celera Diagnostics/Applied 
Biosystems; ViroSeq HIV-1 
genotyping system 
Plasma RNA amplified by PCR Detection by 
capillary electrophoresis.  
Many hrs 
HIV VIRUS 
LOAD 
Roche :Tagman HIV-1 Monitor 
Test v1.5   
Plasma RNA amplified by real-time RT-PCR 
Detection by fluorescence 
(real-time PCR) 
5-6 hrs 
Roche 
Amplicor HIV-1 Monitor Test v1.5 
Plasma/Serum RNA by RT-PCR  
Detection by EIA 
6-8 hrs 
Roche : Cobas Amplicor HIV-1 
Monitor test v1.5 
Plasma/serum RNA amplified by Cobas 
AmpliPrep RT-PCR 
Detection by EIA 
6-8 hrs 
Gene-probe :APTIMA HIV-1 RNA  
Plasma RNA amplified by TMA 
Detection by chemiluminescence 
(hybridization protection assay, HPA) 
5-8 hrs 
Siemens Healthcare Diagnostics  
VERSANT HIV RNA 3.0 Assay 
(bDNA) 
Plasma RNA amplified by RT-PCR Detection by 
chemiluminescence (bDNA) 
Covering HIV-1 subtypes 
50copy/mL DOL 
8 hrs 
Abbott:LCx HIV1 RNA 
quantification kit 
Plasma RNA amplified by RT-PCR 5-8 hrs 
Abbott: Real-Time HIV-1 
Plasma RNA amplified by RT-PCR rTth 
polymerase 
Detection by fluorescence (real-time PCR) 
 
Organon Teknika: (Biomerieux) 
NucliSens EasyQ HIV-1 
Plasma RNA amplified by NASBA 
Detection by Electro-chemiluminescence 
2.5-3 hrs 
Primagen: Retina Rainbow 
(collapsed?) 
Plasma RNA amplified by NASBA 
Detection by  
1.5 hrs 
HIV PROVIRAL 
DNA 
Roche: Amplicor HIV-1 DNA test 
v1.5 
Plasma DNA amplified by PCR 
Detection by EIA 
Case: 1-500µL infant whole blood with DNA 
sample from Rwanda to USA 
7-8 hrs 
Table 6-1 HIV assays and products 
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6.3 BUSINESS OPPORTUNITIES: ISFET PLATFORM HIV NAT 
6.3.1 MARKET OPPORTUNITIES 
Market provides revenue, produces profit, and sustains growth. Thus, it is significant 
to determine if there are demands for a new HIV test product. In section 6.2.2, a 
growth trend of the HIV testing market is foreseeable. Thus, there is a market for a 
more competitive and more cost-effective HIV testing product. 
In chapter 1 we have discussed various sequencing markets, applications, and 
detection techniques. Here in this chapter, we focus on a novel low density genome 
typing methodology for HIV tests. Present day, HIV testing products such as HIV 
tests using NAT systems listed in Table 6-1 HIV assays and products, rapid tests such 
as OraQuick, or antibodies tests such as ELSA and Western bolt are either lab-based, 
require skilled lab personals, very costly or lack of sensitivity before seroconversion. 
Presently, in order to overcome shortcomings in each single HIV test, detecting HIV 
with combinations of different HIV tests as a cocktail solution is the only method to 
resolve the dilemmas.  
6.3.2 BUSINESS OPPORTUNITIES: ISFET PLATFORM HIV NAT 
As we have mentioned in section 6.2.1, the sensitivity and selectively of a HIV test 
are essential. Generally, the sensitivity and selectivity requirement for a standard HIV 
test are 99% and 98% respectively. Thus, as identified in 6.1.2, NAT based tests are 
particularly appropriate for the task where NAT assays in the market have sensitivity 
better than 99% and selectivity better than 99%. However, section 6.1.2 also stated 
that NAT based tests are costly and difficult to implement.  
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As we have mentioned earlier, various chemical sensors have their unique properties, 
characteristics, and flaws. Therefore, there exists a market where users demand a low 
cost, sensitive, and rapid HIV tests. ISFET platform sensors are particularly suitable 
in the case for POC HIV screening tests. There are many comparative advantages 
using such technology in IVD market as it can reduce the costs by leveraging the 
semiconductor industry, while augmenting the efficiency and robustness of HIV tests, 
based on the core technology of NAT.  
6.4 BUSINESS ANALYSIS 
6.4.1 BUSINESS ANALYSIS OVERVIEW 
Here we propose a business model, selling ISFET NAT machines and cartridges to 
clinics, governments, and charity foundations. STP analysis is shown in Table 6-3, 
listing all the potential buyers, market segmentation of this novel application using 
ISFET NAT. Furthermore, a SWOT analysis of the ISFET platform HIV testing is 
illustrated in Table 6-2 to analysis the strength, weakness, opportunities and threats of 
ISFET based NAT. 
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Strength 
 
Currently the only technology for rapid NAT 
detection from a purified and amplified saliva/blood 
sample within 15 minutes ⇒ rapid screening  
 
Scalable mass producible silicon-chip technology 
(CMOS) ⇒ Low cost 
 
Single assay: batch processing not required to 
achieve economics of scale 
 
Accurate – NAT detection ⇒ no “window period”  
 
Therapy support – Rapid NAT viral load test  
 
Disposable cartridge component enhance hygiene 
and repeated revenue  
 
No skilled lab personal needed ⇒ self-test kit  
 
Reduce cost of therapy ⇒ early detection ⇒ early 
therapy ⇒ enhance disease control 
 
Weakness 
 
FDA approval (Timing Consuming)  
 
New testing technology ⇒ Cost to build credibility  
 
Ethical issues 
 
Confidential issues ⇒ Disclosure of personal 
information 
 
Government regulated disease ⇒ difficult for self-
testing market 
 
 
Opportunity 
 
Epidemical World Wide – especially in Africa, 
China and South East Asia  
 
Demands for accurate rapid HIV tests in regions  
lacking skilled personals and laboratory facilities 
 
Effective ⇒ Excludes Window Period  
 
Threats 
 
Government regulations 
 
Liability for false negative  
 
Table 6-2 SWOT ANALYSIS – ISFET PLATFORM HIV TESTING 
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Table 6-3 STP Analysis – HIV Testing Market 
6.4.2 ESTIMATED REVENUE MODEL 
Market Size: Clinics, Governments and Charity Foundations spending on HIV disease 
ISFET NAT Machine Price: 5,000 USD 
Estimate Cost of Machine: 2,000 USD 
Cartridge Price: 5 USD/unit (Price of competitors from 1.5 USD to 5 USD) 
Estimate Cost of Cartridges: 1 USD/unit 
Forecast Machines Sales: 50 units/year 
Forecast Cartridges Sales: 100,000 units/year  
Segmentation:
Rapid screening during window period
Niche market for rapid NAT detections
Cost-effective low density typing machine
Target Markets:
Government (Medical Centers, Hospitals, and Clinic office)
Machines and Cartridges 
USAIDS
Worry wells – end consumers (unregulated regions)
Self-test kit in retails
Charity Foundations
Gates Foundation
William J. Clinton Foundation
Clinics for rapid detection
Position in the Market:
Clinic ISFET NAT Machine Vendor
HIV Testing Kit Supplier 
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Forecast Revenue: 750,000 USD/year 
Forecast Gross Margin: 550,000 USD/year 
6.5 CONCLUSION 
In this chapter, we proposed HIV diagnosis as the suitable application for DNA Logic.  
From the perspective of the global market of HIV testing, there is a growing demand 
for more cost-effect devices with better sensitivity. The impact of the new infection is 
significant on the life of individuals. The market and healthcare system need to 
narrow the non-responsive period of the current methods. DNA Logic differentiates 
from other NATs because the POC factor. In regions with less resources, HIV test in 
POC would have saved many infections and managed more treatment regimes that are 
more responsive. ISFET based NAT has all the ingredients to fill the need, such as 
right technology, proved manufacturability, lower cost, and strong market. HIV 
diagnosis is only one of DNA Logic applications. It has a great potential to be an 
important player in the diagnostic business.   
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CHAPTER 7 FUTURE WORK ON APPLICATIONS 
AND CONCLUSIONS 
7.1 FUTURE WORK ON NAT APPLICATIONS 
In previous chapters, we have shown the feasibility of using ISFET platform nucleic 
acid testing (NAT) to perform a HIV test. In addition, we also depicted and analyzed 
a business model selling ISFET NAT machines and cartridges for the detection of 
HIV/AIDS. However, as mentioned in the earlier chapter, the ISFTE technology is a 
platform technology. ISFET NAT not only is useful in HIV/AIDS application but it 
can also detect any genes of interest. In other words, this method is capable of 
detecting any nucleic acid sequence in any living organism. Thus, here we proposed 
some critical applications especially in infectious disease and pathogen detection 
could be benefited from POC NAT technologies such as ISFET platform. Two 
examples are given below, H1N1 and Chlamydia.  
7.1.1 HIN1 
In April 2009 H1N1, a new influenza virus is first detected in the United States 
causing illness in people. The novel strain is virulent and live threatening. Among the 
whole possible H1N1 infected individual in the US States, it is about 0.4% to be 
hospitalised as shown in Table 7-1. This epidemic is spreading rapidly around the 
world similar as regular seasonal influenza viruses. On June 11, 2009, WHO 
announced the emergence of H1N1 as a pandemic underway and raised the level of 
influenza pandemic alert from phase 4 (sustained human to human transmission) to 
phase 5 (widespread human infection).  
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2009 H1N1 Mid-Level Range Estimated Range 
Cases     
0-17 years ~20 million ~14 million to ~28 million 
18-64 years ~35 million ~25 million to ~52 million 
65 years and older ~6 million ~4 million to ~9 million 
Cases Total ~61 million ~43 million to ~89 million 
Hospitalisations     
0-17 years ~87,000 ~62,000 to ~128,000 
18-64 years ~160,000 ~114,000 to ~235,000 
65 years and older ~27,000 ~19,000 to ~40,000 
Hospitalisations Total ~274,000 ~195,000 to ~403,000 
Deaths     
0-17 years ~1,280 ~910 to ~1,880 
18-64 years ~9,570 ~6,800 to ~14,040 
65 years and older ~1,620 ~1,160 to ~2,380 
Deaths Total ~12,470 ~8,870 to ~18,300 
Table 7-1: H1N1 case and related deaths in US from April 2009 to April 2010[134] 
 Certain people are at high risk of serious complications, including severe illness and 
death. These people at high risk include old people from 65 years and older, young 
children less than five years old, pregnant women, and people with chronic medical 
conditions. Thus, once a case is confirmed, treatment should be initiated as early as 
possible. According to studies, therapies and treatments are most effective in the first 
2 days of illness. However, the typical incubation period for influenza is 1-4 days. 
Therefore, early detection of the virus is essential to support effective treatments. 
New mutated influenza emerges every couple years and the emergence cycle of 
mutating influenza has shortened in the past few years due to missuses and overuse of 
antibiotics.  
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Early detection or self-diagnosis will prevent and stop virus spreading. The 
requirement for a fast development to accommodate the novel mutation eliminates the 
antibody-based detection based methods. Developing rapid ISFET NAT screening for 
H1N1 can help epidemic control and achieve early detection for early treatments to 
save life s from severe illness and death. 
7.1.2 CHLAMYDIA 
Chlamydia is a very common sexually transmitted disease (STD) caused by the 
bacterium, Chlamydia trachomatis.  Symptoms of Chlamydia are often mild or absent, 
but serious irreversible complications, including infertility, can occur "silently" before 
a woman ever recognizes a problem.  
Chlamydia is the most frequently reported bacterial sexually transmitted disease in the 
United States.  In 2006, 1,030,911 Chlamydial infections were reported to the CDC, 
and this is a vast underestimate of the true number of infections; true figures are at 
least double this.  A conservative estimate indicates that more than 90 million people 
a year get infected with Chlamydia.  Chlamydia can be transmitted during vaginal, 
anal, or oral sex and it can also be passed from an infected mother to her baby during 
childbirth. Chlamydia can also be found in the throats of women and men having oral 
sex with an infected partner. In addition, women infected with Chlamydia are up to 
five times more likely to become infected with HIV, if exposed. 
To help prevent the serious consequences of Chlamydia, screening at least annually 
for Chlamydia is recommended for all sexually active women age 25 years and 
younger. An annual screening test also is recommended for older women with risk 
factors for Chlamydia. All pregnant women should have a screening test for 
Chlamydia. 
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In pregnant women, there is some evidence that untreated Chlamydial infections can 
lead to premature delivery. Babies who are born to infected mothers can get 
Chlamydial infections in their eyes and respiratory tracts. Chlamydia is a leading 
cause of early infant pneumonia and conjunctivitis in new-borns. 
There is a need for a rapid test for chlamydia but the current rapid tests are not 
sensitive in the low prevalence environment [135, 136].There are no good antibody 
tests for Chlamydia due to their poor specificity and low sensitivity.  The current gold 
standard is the laboratory nucleic acid test (NAT). These are exclusively PCR based, 
requiring expensive laboratory equipment. Thus, using the ISFET NAT, such 
concealed STD can be effectively identified and monitored at a very low cost. 
7.2 CONCLUSIONS 
It is only about half a decade since Watson and Crick published the X-ray structure of 
DNA and proposed the complementary double-strands DNA helix [32]. The 
knowledge of the chemical structure of DNA is the basis of modern genetics and 
molecular diagnostics. The advance of technical development has help to accelerate 
the process. The first human genome draft mapping released in 2003 took 13 years to 
finish. Within a few years after the genome publication, the first low-cost sequencer 
from 454 Life Sciences was released, which achieved the whole human genome 
mapping in one week with cost only a fraction of the Human Genome Project. The 
speed of the technology is partly driven by the urge for knowledge of genetic 
information. Pharmacogenetics has been established to consolidate the correlation 
between gene variation and drug response. Molecular diagnostics has been utilising 
the genomic information of pathogens for more sensitive test. The DNA Logic 
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described in the thesis holds a key to unlock the genetic information accumulated so 
far and offer a unique solution for molecular diagnosis.  
Nucleic acid testing is moving into a new phase. In this thesis we have depicted the 
transformation of the technology from a lab-based labelled test to an ISFET label-free 
NAT, allowing complex genetic/specific gene and genomic tests into back-offices or 
even on the store’s counter. This rapid progress in genome science, stimulating vast 
potential of applications, has spurred observers to predict that medical biology will be 
the foremost science of the 21st century.  
From ISFET platform NAT, DNA Logic was derived to make local intelligent 
computations. This not only allows users to see vast intelligent results but also 
enhances the performance and the robustness of the test. 
Various applications can be derived from the ISFET platform NAT. One of the 
applications illustrated in this thesis is the detection of HIV/AIDS. We have made an 
unprecedented proof of science using an ISFET to detect HIV. This major 
breakthrough has proven the feasibility of using this platform to detect HIV in any 
POC setting. In conclusion, in this thesis we have shown vast applications using 
ISFET based NAT and the feasibility of using it as a HIV test. We have also depicted 
a business model showing the possibility of using such technology as a platform for 
pathogen detection.  
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